 
CONFIDENTIAL  CLINICAL RESEARCH PROTOCOL   
 
 
  
 
  
 
 
A Phase I/ II Randomized Placebo- Controlled, Double -Blind, Single -Center, 
Tolerability and Preliminary Efficacy Clinical Trial of Intravenous Immunoglobulin 
(IVIG)  Eye Drops In Patients with Dry Eye Disease  
 
  
 
 
Regulatory Sponsor:   
Sandeep Jain, MD  
UIC Corneal Neurobiology Laboratory  
Room L239, LIERI  
[ADDRESS_1091182].  
Chicago, IL [ZIP_CODE]  
Phone: 312- 996-8936  
Fax: 312 -996-7770  
 
Funding Sponsor:   
 
Study Product:  Intravenous Immunoglobulin (IVIG)  Eye Drops  
 
Protocol Number:  2019- 0263  
IND Number:  [ZIP_CODE] 
 
  Initial version:   3.0; 04/09/ 2019  
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019  Page 2 of 59 
 
2 
  
Table of Contents  
ABBREVIATIONS  .................................................................................................................................................... 7  
STUDY SUMMARY  .................................................................................................................................................. 8  
1 BACKGROUND & RATIONA LE ....................................................................................................................... 10 
1.1 INTRODUCTION  ................................................................................................................................................ 10 
1.2 DRY EYE DISEASE : DEFINITION AND PATHOGENESIS  ................................................................................................. 10 
1.3 DRY EYE DISEASE : PATHOGENESIS – AUTOIMMUNE INFLAMMATION  .......................................................................... 11 
1.3.1  Immunoglobulins are increased in tear fluid of Dry Eye Disease patients:  .......................................... 11 
1.3.2  Immunoglobulins are produced locally by [CONTACT_791404]:  ........................................................... 12 
1.3.3  Autoantibodies are present in tear fluid in ocular surface disease:  ..................................................... 13 
1.4 DRY EYE DISEASE : CLINICAL SIGNS AND SYMPTOMS  ................................................................................................ 15 
1.5 DRY EYE DISEASE : DIAGNOSTIC TESTING  ............................................................................................................... 17 
1.6 DRY EYE DISEASE : CURRENT MANAGEMENT  .......................................................................................................... 18 
1.7 SCIENTIFIC RATIONALE FOR IVIG  EYE DROPS IN DRY EYE DISEASE  ............................................................................... 18 
1.8 SPECIFIC AGENT IN THIS STUDY  ............................................................................................................................ 22 
1.9 SAFETY STUDIES  ............................................................................................................................................... 23 
1.10 TISSUE DISTRIBUTION STUDIES  ............................................................................................................................ 24 
1.11 IVIG  ANIMAL EFFICA CY AND CLINICAL DATA TO DATE ............................................................................................. 25 
1.11.1  IVIG Animal Efficacy Data  .................................................................................................................... 25 
1.11.2  IVIG Clinical Data to Date  .................................................................................................................... 26 
1.12 DOSE RATIONALE AND RISK/BENEFITS  .................................................................................................................. 28 
2 STUDY OBJECTIVES  ....................................................................................................................................... 29 
3 STUDY DESIGN  ............................................................................................................................................. 29 
3.1 GENERAL DESIGN .............................................................................................................................................. 29 
3.2 TOLERABILITY END POINT: TEST SUBSTANCE TOLERANCE (VISUAL ANALOGUE SCALE) .................................................... 30 
3.3 SECONDARY STUDY ENDPOINT  ............................................................................................................................ 30 
3.4 EXPLORATORY STUDY ENDPOINTS  ........................................................................................................................ 30 
3.4.1  Exploratory Efficacy End Point: Ocular surface Lissamine Dye staining score ..................................... 31 
3.4.2  Exploratory Efficacy End Point: Ocular Surface Disease Index (OSDI)  .................................................. 31 
3.4.3  Exploratory Efficacy End Point: Clinical Global Impression (C GI) ......................................................... 32 
3.4.4  Exploratory Efficacy End Point: Subject Global Assessment (SGA)  ....................................................... 33 
3.4.5  Exploratory Efficacy End Point: Ocular surface redness  score  ............................................................. 33 
3.4.6  Exploratory Efficacy End Point: Keratograph Oculus Redness Score  .................................................... 34 
3.4.7  Exploratory Efficacy End Point: InflammaDry for MM P-9 Protein  ....................................................... 35 
3.4.8  Exploratory Efficacy End Point: Symptom (Ocular Discomfort) Intensity  ............................................. 35 
3.5 SAFETY ENDPOINTS  ........................................................................................................................................... 36 
3.5.1  Vital Signs  ............................................................................................................................................ 36 
3.5.2  Ophthalmic Examination  ..................................................................................................................... 36 
3.6 OTHER STUDY PROCEDURES : OCULAR SURFACE WASHINGS  ...................................................................................... [ADDRESS_1091183] RECRUITMENT AND SCREENING  ............................................................................................................... 38 
4.4 EARLY WITHDRAWAL OF SUBJECTS  ....................................................................................................................... 39 
4.4.1  When and How to Withdraw Subjects  ................................................................................................. 39 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019  Page 3 of 59 
 
3 
 4.4.2  Data Collection and Follow -up for Withdrawn Subjects  ...................................................................... 39 
5 STUDY DRUG  ................................................................................................................................................ 39 
5.1 DESCRIPTION  ................................................................................................................................................... 39 
5.2 TREATMENT REGIMEN  ....................................................................................................................................... 40 
5.3 METHOD FOR ASSIGNING SUBJECTS TO TREATMENT GROUPS .................................................................................... 40 
5.4 PREPARATION AND ADMINISTRATION OF STUDY DRUG ............................................................................................ 40 
INSTRUCTIONS FOR DRU G USE:  ........................................................................................................................... [ADDRESS_1091184] ENROLLMENT  ....................................................................................................................................... 45 
6.5 STUDY ASSESSM ENTS ........................................................................................................................................ 45 
6.5.1  Visit 1 Screening  ................................................................................................................................... 45 
6.5.2  Visit 2 Day 1 (Randomization and First treatment visit)  ...................................................................... 46 
6.5.3  Visit 3: Week 4 (± 4 days)  ..................................................................................................................... 47 
6.5.4  Visit 4: Week 8 (± 4 days)  ..................................................................................................................... 47 
6.5.5  Visit 5: Week 10 (± 4 days)  ................................................................................................................... [ADDRESS_1091185] POPULATION (S) FOR ANALYSIS  ................................................................................................................ 48 
8 SAFETY AND ADVERSE E VENTS  ..................................................................................................................... 49 
8.1 ADVERSE EVENT DEFINITIONS  ............................................................................................................................. 49 
8.2 CLASSIFICATION OF ADVERSE EVENTS BY [CONTACT_86919]  .................................................................................................. 50 
8.3 ACTION (S) TAKEN  ............................................................................................................................................. 51 
8.4 OUTCOME  ....................................................................................................................................................... 51 
8.5 ADVERSE EVENT REPORTING  ............................................................................................................................... 51 
8.6 SERIOUS ADVERSE EVENT REPORTING  ................................................................................................................... 51 
8.7 IN CASE OF AN EMERGENCY  ................................................................................................................................ 52 
8.8 DATA SAFETY MANAGEMENT PLAN ...................................................................................................................... 52 
8.9 STUDY OVERSIGHT  ............................................................................................................................................ 53 
9 CONFIDENTIALITY  ........................................................................................................................................ 53 
10 SOURCE DOCUMENTS  .............................................................................................................................. 53 
10.1 RECORDS RETENTION  ........................................................................................................................................ 54 
11 ETHICAL CONSIDERATIONS  ....................................................................................................................... 54 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- [ADDRESS_1091186] STIPENDS OR PAYMENTS  ........................................................................................................................ 54 
13 REFERENCES:  ............................................................................................................................................ 56 
 
 
 
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019  Page 5 of 59 
 
5 
  
SCHEDULE OF VISITS AND PROCE DURES  
 
 
Screening  
Day 1   
(Pre-Dose)  
Day 1  
(Post -Dose)  
Week 4  
Week 8  
Week 10  
Informed c onsent X      
Demographic i nformation  X      
Medical h istory/  Con Meds  X      
Ophthalmic/ Dry Eye h istory  X      
Vital signs  X  X X X 
Visual Acuity (Snellen’s ch art) with eye 
glasses (if applicable)   X  X X X 
Ocular Surface Disease Index (OSDI) X X  X X X 
Clinical Global Impression  (CGI)     X X X 
Subject Global Assessment  (SGA)     X X X 
Test Substance Tolerance (VAS)    X X X  
Ophthalmic e xamination (Slit lamp ) X X  X X X 
Schirmer I test  X X   X  
Lissamine Dye staining  X X   X  
Ocular surface Redness (OR) score  X X  X X X 
Ocular surface wash collection for 
analysis   X   X  
Keratograph Oculus Redness Score   X   X  
Non-invasive Keratography Tear Film 
Break -up Time (NIKBUT)   X   X  
Symptom Intensity Assesment  X  X X X 
InflammaDry for MMP -[ADDRESS_1091187] study m edication   X     
Drug dispensation visits    X X   
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019  Page 6 of 59 
 
6 
 Instruction on study medication se lf-
administration    X    
Adverse Events/  Concomitant Medications   X X++ X X X 
*If applicable    ++ AEs only  
 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- [ADDRESS_1091188] 
ICH   International Conference on Harmonization  
IB   Investigator’s Brochure  
IOP   Intraocular pressure  
IRB   Institutional Review Board 
IgA  Immunoglobulin A  
IgG  Immunoglobulin G  
KCS   Keratoconjunctivitis sicca 
LFU  Lacrimal Functional U nit 
NET  N eutrophil extracellular trap 
NIKBUT  Non-invasi ve Keratograph Tear Film Break -Up Time  
oGVHD ocular Graft -vs-Host Disease  
OSD   Ocular Surface D isease  
OSDI   Ocular Surface Disease Index  
OTC   O ver the counter  
BID  Two times per day  
IVIG   Intravenous Immunoglobuline  
SAE   Serious Adverse Event  
SANDE  S ymptom Assessment in Dry Eye 
SGA  Subject Global Assessment  
SPEED  Standardized Patient Evaluation of Eye Dryness  
SS  Sjogren S yndrome  
UIC   University of Illinois at Chicago  
VA   Visual Acuity  
VAS  Visual Analog Scale  
VBR  Validated Bulbar Redness  
 
 
 
  
 
IVIG-eye drops  treatment for Dry Eye Disease   Page 8 of 59 
Version: 3.0; 04-09- 2019 
CONFIDENTIAL  Stud y Summary  
Title A Phase I/II Randomized Placebo -Controlled , Double -Blind  Single -
Center, tolerability and preliminary efficacy clinical trial of Intravenous 
Immunoglobulin  (IVIG)  eye drops in patients with Dry Eye Disease  
Short Title IVIG-eye drops  treatme nt for Dry Eye Disease  
Protocol Number   
Phase Phase I/II  
Methodology  Double- blind  
Study Duration  10 weeks  
Study Center(s)  Single -center  
Objectives  To evaluate the safety  and preliminary efficacy of IVIG-eye drops in 
patients with Dry Eye Disease . 
Number of Subjects  24 (study drug - 12, placebo- 12) 
Diagnosis and Main 
Inclusion Criteria  Men and women ≥ 18 y ears of age with a diagnosis of Dry Eye 
Disease , with Schirmer’s test ≥ 0 to ≤ 9  mm/5min , Ocular surface 
staining ≥1 and OSDI mild (≥13), with high  ACPA (> 4.4 units) in ocular 
surface wash  
Study Product, 
Dose, Route, 
Regimen  Study drug:  Intravenous Immunoglobulin (IVIG) , 4 mg/ml  (0.4%)  eye 
drops two times a day for eight  weeks .  
Control : Normal Saline Eye Drops  (0.9% NaCl)  
Duration of administration 8 weeks  
Reference therapy  Normal Saline  eye drops two times a day for eight weeks.  
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 9 of 59 
 
9 
 Statistical 
Methodology  Based on  the classification of reasons for conducting pi[INVESTIGATOR_791352], in this pi[INVESTIGATOR_791353] (i) Process – recruitment 
rate, retention rate, (non)compliance or adherence rate; and (ii) 
Scientific – safety (adverse event/SAE rate), tolerability, and e fficacy , 
including  reduction in clinical signs and symptoms (OSDI, Corneal 
staining, Redness etc) and treatment effect size.  We will calculate the 
observed rate with 95% confidence interval for each rate by [CONTACT_6490]. Other descriptive statistics, including median with interquartile or 
mean with standard deviation for continuous variables and frequency 
with percentage for  categorical variables will be reported as well.  To 
estimate the preliminary efficacy under the scientific category, one eye 
(target eye) will be selected at screening visit as follows: (i) if only 1 eye 
meets inclusion criteria, this eye is used; (ii) if both eyes meet inclusion criteria, the eye with the higher  corneal stain score is used; (iii) if both 
eyes have the same corneal stain 
score, then the one with the lower 
Schirmer I score is used; (iv) if both eyes have same scores, the right 
eye is used. Secondary analyses will be performed for the non-target 
eye as well.  Due to the nature of this feasibility study, any efficacy 
statistical tests and adjusted analyses will not be conducted.  Detailed 
data validation will examine completeness, existence and accuracy of 
collected data to assess data quality and identify missing and 
conflicting data.  Statistical analysis will be performed on an intention -to-
treat basis i.e., inclusion of patients randomly assigned, regardless of 
adherence, actual treatment rece ived, and subsequent withdrawal of 
treatment and/or deviation from the protocol and per -protocol (i.e., 
inclusion of those who completed the treatment as planned)1 and will 
be reported according to 2010 CONSORT guidelines.2 All statistical 
analyses will be completed using SPSS Statistics V.22.0.31  
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 10 of 59 
 
10 
 1 Background & Rationale  
1.1 Introduction 
 
The sponsor -investigator (Sandeep Jain, MD) is initiating clinical investigations using  Intravenous 
Immune Globulin (IVIG) eye drops  0.4% for the treatment of Dry Eye Disease (DED)  in patients who 
have demonstrated presence of anti -citrullinated protein antibodies (ACPAs  > 4.4 units  in ocular 
surface wash) over the ocular surface.  IVIG-eye drop  is a fractionated plasma product comprising 
Immunoglobulin G (IgG ) that offers significant advantages over unlicensed blood- derived eye drops  
(unfractionated serum or plasma  eye drops ). IVIG is currently an FDA approved product that is 
available from Grifols [LOCATION_003], LLC as  Flebogamma 5% DIF immune globulin intravenous (human), 
indicated for treatment of primary (inherited) immunodeficiency (PI) in adults and pediatric  patients 2 
years of age and older . Flebogamma 5% DIF will be repurposed as IVIG -eye drops by [CONTACT_791405] 4mg/ml ( 0.4% ) dose.   
 
We have discovered that citrullinated proteins  are present  on the ocular surface of patients with DED 
and further discovered that anti-citrullinated  protein antibodies (ACPA) are also present in the tear fluid 
of these patients  (Figure 3). We also discovered that receptors (Fc -gamma 1) for these IgG 
autoantibodies are expressed on the ocular surface of neutrophils and dendritic cells and found 
evidence of engagement of IgG with Fc -gamma 1 receptors  (Figures 6 & 7 ). Based on these findings, 
we hypothesized that IgG autoantibodies in the tear fluid contribute to ocular surface inflammation via 
interaction with Fc-gamma 1 receptors. In a murine model, we demonstrated that topi[INVESTIGATOR_791354] (Figure 12  A1, A2)  and competition with topi[INVESTIGATOR_791355] (Figure 12 A3, A4 ). We also found that a topi[INVESTIGATOR_791356] -eye drops 
(4mg/ml) to murine eye does not cause ocular surface toxicity (Figure 9 ). Given these findings, we 
propose a feasibility clinical trial using IVIG eye drops to treat ocular surface disease in  patients 
with DED who have high ACPA in the tear fluid.  
 This document is a protocol for a human research study. This study is to be conducted according to US 
and international standards of Good Clinical Practice (FDA Title 21 part 312 and International 
Conference on Harmonization guidelines), applicable government regulations and Institutional research 
policies and procedures.  
1.2 Dry Eye Disease: Definition and Pathogenesis  
 
Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the 
tear film, and accompanied by [CONTACT_72069], in which tear film instability and hyperosmolarity, 
ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles.3 DED 
is also recognized as keratoconjunctivitis sicca (KCS), sicca syndrome, keratitis sicca, xerophthalmia, 
dry eye syndrome (DES), dysfunctional tear syndrome (DTS), ocular surface disease (OSD) or dry eye. 
DED is caused by [CONTACT_677766]. Tear film instability can be triggered by 
[CONTACT_791406], or by [CONTACT_791407]4, 5. 
Furthermore, dry eye is typi[INVESTIGATOR_677727]:  
 1) Aqueous tear deficient dry eye disease  
2) Evaporative dry eye disease  
 
As DED progresses, lacrimal gland obstruction, meibomian gland orifice obstruction, thickened eyelid 
margins, cloudy, solid, or granular meibum secretion, eyelid telangiectasia, and meibomian gland 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 11 of 59 
 
11 
 dysfunction become common clinical features. In advanced cases, dry eye can cause fibrotic thi ckening 
of the cornea and conjunctiva, filamentous keratitis, mucoid clumpi[INVESTIGATOR_007], trichiasis, symblepharon, 
keratinization of the eyelids and meibomian glands, corneal and conjunctival erosion and thinning, 
corneal and conjunctival neovascularization, corneal  and conjunctival scarring, corneal ulceration, and 
corneal perforation. In addition, prolonged ocular surface inflammation can lead to moderate or absolute loss/atrophy of the meibomian glands, lacrimal glands, and conjunctival goblet cells, and subsequen tly a dramatic reduction in tear film production and the onset of permanent DED
6.  
 DED prevalence increases with age. The most common causes of dry eye are contact [CONTACT_617879], 
autoimmune disorders, systemic drug effects, and refractive surgeries, particularly in middle- aged and 
older adults. DED also occurs in a higher percentage of women than men, especially in women 
entering menopause or pregnancy; hormone imbalances during menopause or  pregnancy can cause 
lacrimal gland and ocular surface inflammation and tear film abnormalities
4. 
1.3 Dry Eye Disease: Pathogenesis – Autoimmune Inflammation  
 
DED is a result of changes to the lacrimal functional unit (LFU). The LFU is composed of the lacrimal  
glands, cornea, eyelids, meibomian glands, conjunctiva, goblet cells, and ocular nerves. The LFU is responsible for the sustained production of adequate tear film to consistently lubricate the ocular surface. Structural changes to the LFU can induce tear film instability and insufficiency, which in turn 
can lead to tear hyperosmolarity. Chronic osmotic stress from tear film can activate stress associated 
pathways in ocular surface epi[INVESTIGATOR_1663], thereby [CONTACT_178521] a pro -inflammatory response that involv es 
a mix of chemokines, cytokines, and matrix metalloproteinases. The subsequent maturation of antigen-presenting cells (APC’s) on the ocular surface leads to the migration, activation, and expansion of autoreactive T cell lymphocytes as well as other leuk ocytic classes in the LFU. The constant 
recruitment of pro- inflammatory leukocytes onto the ocular surface inflicts epi[INVESTIGATOR_791357]
7, 8. These abrasions can eventually progress to 
superficial punctuate keratitis, squamous metaplasia, extracellular matrix deposits, decreased goblet 
cell differentiation, increased epi[INVESTIGATOR_677729] (epi[INVESTIGATOR_15424]), and significant ocular surface nerve damage and neuropathy.   
1.3.1  Immunoglobulins are increased in tear fluid of Dry Eye Disease patients :  
 
Immunoglobulins are a principal tear proteins that are directly secreted by [CONTACT_791408], epi[INVESTIGATOR_5169] (EGF) and tear lipocalin.9 Some tear proteins are derived from 
serum, such as albumin, transferrin, IgG and IgM probably as a result of leakage from the blood 
vessels. It is also known that cell infiltrating conjunctiva ( plasma cells ) secrete immunoglobulins  and 
cytokines in various conditions. There is general agreement  that IgA is the pre- dominant tear 
immunoglobulin.10 IgA concentration in tears varies between 0.14 mg/ml – 0.40 mg/ml. IgG 
concentration in tears  collected from the ocular surface  is much less than IgA, reported as 0.02 mg/ml 
or undetectable,  [ADDRESS_1091189] higher IgG amounts (0.23 
mg/ml).12 Therefore the IgA/IgG ratio in normal tears is >1.0. Our clinical data  show s that patients 
with DED have abundant amounts of immunoglobulins in the tear fluid and the predominant 
immunoglobulin is IgG  (Figure 1) . 
 
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 12 of 59 
 
12 
 
 
Figure 1: Total immunoglobulin amount in tear fluid of DED patients.  We determined whether 
immunoglobulins were increased in tear fluids of DED patients . We performed ocular surface washings 
in healthy subjects (n=36 eyes) and patients with DED due to Sjogren’s syndrome (n=41 eyes). Ocular 
surface washings were performed and analyzed for human immunoglobulin total amount and isotype 
distribution using Human Immunoglobulin Isotypi[INVESTIGATOR_791358] (Cat. No. HGAMMAG -301K, 
EMD Millipore, Billerica, MA). A. The amount of immunoglobulins in Sjogren’s syndrome patients 
(26,389.2±8,090.4 ng/mL; p<0.05) was significantly higher as compared to healthy subjects 
(130.0±26.7 ng/mL), which represents more than 200 fold higher amou nt.  B. The immunoglobulin 
isotype distribution was different in Sjogren’s syndrome patients as compared to healthy subjects. In 
Sjogren’s syndrome IgG was the dominant immunoglobulin comprising 92% of immunoglobulins. In 
healthy subjects IgA (42%) and IgG  (43%) were the dominant immunoglobulins. Taken together, 
these experiments showed that patients with DED due to Sjogren’s syndrome have abundant 
amounts of IgG in the tear fluid.  
1.3.2  Immunoglobulins  are produced locally by [CONTACT_791404] :  
 
The human conjunctiva and lacrimal drainage system have an associated lymphoid tissue that is 
capable of detecting antigens and inducing a complete immune response by [CONTACT_791409].[ADDRESS_1091190] for 
a needle- free vaccine administration strategy, ocular conjunctiva has been evaluated as an alternative 
mucosal immunization route. Conjunctival immunization with tetanus toxoid (TTd)  induced TTd -specific 
local and systemic immune responses.[ADDRESS_1091191] ocular surface cells  (Figure 2A), suggesting active immune processing.  Our data 
also shows  the presence of IgG containing Plasma cells on the ocular surface (Figure 2B) , suggesting 
antibody production and secretion by [CONTACT_791410].  Taken together, our data shows that all cellular 
players that are needed for inducing an immune response are present on the surface of the eye.  
 
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 13 of 59 
 
13 
 
 
Figure 2: Immunofluorescence staining of Plasma cells and Immunoglobulins (IgG)  in 
conjunctival impression cytology specimen obtained from patient with DED due to Sjogren’s 
Syndrome.  Conjunctival impression cytology was performed on Sjogren’s Syndrome patients to 
determine whether the cellular components necessary for immune response are present on the ocular 
surface. These cells include antigen processing B cells (CD19 positive), T -helper cells (CD4 positive) 
and immunoglobulin secreting Plasma cells (CD138). Impression filter papers were processed for 
immunofluorescence staining with anti -CD4 antibody (mouse monoclonal anti CD4 antibody; R&D 
Systems, #MAB379, 1:50), anti- CD19 antibody (rabbit monoclonal anti CD19 antibody; Abcam, 
#ab134114, 1:20), anti -CD138 antibody (mouse monoclonal anti CD138 antibody; Bio- Rad, 
MCA2459GA, 1:500), and anti- IgG antibody (rabbit monoclonal anti human IgG antibody; Abcam, 
#ab109489, 1:500) and confocal immunofluorescence microscopy was performed to localize the 
proteins. Figure 2A2 shows the T -helper cells (red) and figure 2A3 shows the B cells (green) . The T 
cells and B cells are in close proximity (inset box in 2A4), suggesting active immune 
processing.  Figure 2B2 shows the presence of Plasma cells (red) and figure 2B3 shows the presence 
of IgG (green). Plasma cell and IgG co- localize (figure 2B4), suggesting that there may be 
antibody production and secretion by [CONTACT_791411]’s Syndrome.    
1.3.3  Autoantibodies are present in tear fluid  in ocular surface disease:  
 
Autoantibodies have been detected in tears of patients in the context of ocular diseases. Anti -HSV IgG 
is present in tear fluid of patients with HSV keratitis and the pres ence of anti -HSV IgG in tears i s 
significantly associated with decreased corneal sensation, presence of stromal opacities, and with 
neurotrophic keratitis.16 In Chlamydia trachomatis, the leading global cause of preventable blindness, 
significantly higher anti -chlamydial protein IgG levels are found in the tear fluid of inflammatory 
trachoma cases as compared with levels in the controls.17 Several autoantibodies ( anti-SS-A, anti-SS-
B, and anti- DNase I)  are present in tear fluid of  Sjogren syndrome (SS) patients. These autoantibodies 
(anti-SS-A and anti -SS-B) are present in tears even though they are not detectable in the s erum of 
Sjögren’s syndrome patients, suggesting that anti -SS-A or anti -SS-B IgG synthesis may occur within 
lacrimal glands/ocular surface tissues.18 Our clinical data shows the presence of  citrullinated 
proteins  over  the ocular surface and the presence of anti-citrullinated protein antibodies 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 14 of 59 
 
14 
 (ACPAs) in the tear fluid of several DED subtypes (Figure 3). We are the first to discover the 
presence of ACPAs in tear fluid of DED patients.  
 
 
 
Figure 3:  Presence of anti -citrullinated protein autoantibodies (ACPAs) in tear fluid of patients 
with DED. We determined the amount of ACPAs in the tear fluid of patients with DED and healthy 
subjects . Ocular surface washings were performed and analyzed for the presence and amount of 
ACPA using a semi- quantitative enzyme- linked immunosorbent assay (Quanta Lite CCP 3.1, Inova 
Diagnostics, San Diego, CA). Based on a 98th percentile value of ACPA amount in healthy subjects, 
we determined 4.4 units of ACPA to be the cutoff threshold above which values were considered 
positive  for the presence of ACPA in tear fluid. We calculated the ACPA amount (units, median) in tear 
fluid of eyes that wer e positive for ACPA (i.e. ACPA  > 4.4 units) and further calculated the percent of 
eyes that were ACPA positive (i.e. ACPA  > 4.4 units) for each DED subtype. ACPAs were present in 
the tear fluid of many DED subtypes such as: (i) Sjogren’s syndrome (13.8 units median in 40.9% of 54 
eyes); (ii) tear deficient non- Sjogren’s DED (13.0 units median in 47.8% of 54 eyes); (iii) meibomian 
gland dysfunction (MGD) (13.1 units median in 31.1% of 33 eyes); (iv) ocular rosacea (9.2 units median 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 15 of 59 
 
15 
 in 39.3% of 11 eyes); (v) symptom sign disconnect (27.5 units median in 50.0% of 20 eyes); (vi) mixed 
mechanism (26.7 units median in 31.3% of 15 eyes); (vii) Superior limbic keratoconjunctivitis (SLK) 
(12.4 units median in 43.3% of 29 eyes); (viii) neurotrophic cornea (35.7 units median in 50% of 14 
eyes); (ix) ocular cicatricial pemphigoid (OCP) (10.4 units median in 55.6% of 10 eyes); (x) Steven 
Johnson syndrome (50.6 units median in 27.3% of 3 eyes); (xi) none oGVHD (10.8 units median in 16% 
of 20 eyes) and (xii) definite oGVHD (13.7 units median in 15.3% of 21 eyes). Taken together, these 
data show that several DED subtypes have presence of ACPA in the tear fluid.   
 
 
Figure 4: Presence of non- ACPA autoantibodies in DED due to Sjogren’s syndrome. We 
determined whether autoantibodies other than ACPAs were also present in tear fluid of patients with 
Sjogren’s syndrome. We performed ocular surface washings in healthy subjects (n=14 eyes) and 
patients with DED due to Sjogren’s syndrome (n=27 eyes). Ocular surface washings were analyzed for 
the presence of non -ACPA autoantibodies using Human Autoimmune Autoantibody MILLIPLEX MAP 
kit (Cat. No. HAIAB -10K, EMD Millipore, Billerica, MA). Several autoantibodies were detected: (i) 
SSA/RO60 (260 folds higher amount than healthy); (ii) SSA/RO52 (178 folds higher amount than 
healthy); (iii) SSB/LA (54 folds higher amount than healthy); (iv) CENP -A (147 folds higher amount than 
healthy) and (v) CENP- B (173 folds higher amount than healthy). This data shows that several 
autoantibodies were present in the tear fluid of Sjogren’s syndrome patients.  
1.4 Dry Eye Disease: Clinical Signs and Symptoms  
 
Common signs and symptoms of DED include:  eye redness, ocular pain, burning and stinging 
sensation, foreign body sensation, pruritus, itchy or scratchy eye sensation, tired eyes, enhanced eye 
pressure, photophobia, painful mucous discharge, and in some cases epi[INVESTIGATOR_119230]. DED typi[INVESTIGATOR_791359]. Dry eye can heavily impact visual function especially during visually intensive activities 
and can overall decrease quality of life.4, [ADDRESS_1091192]  more severe signs of DED  (Table 1). 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 16 of 59 
 
16 
 
 
Table 1: Comparison of clinical signs and symptoms of DED in patients who have presence of 
anti-citrullinated antibodies in tear fluid (ACPA+) or serum (CCP+) with those who do not have 
these antibodies in tear fluid (ACPA -) or serum (CCP -). It is known that rheumatoid arthritis patients 
who have ACPA antibodies in serum have more severe joint disease, therefore we determined whether 
patients who have presence of ACPA in tear fluid similarly have more severe ocular surface disease. 
The presence of A CPA in tear fluid of DED patients (n=322 eyes) was determined using a semi -
quantitative enzyme- linked immunosorbent assay (Quanta Lite CCP 3.1, Inova Diagnostics, San Diego, 
CA). Pati ents who had tear fluid ACPA>4.4 units were considered positive (ACPA+). The presence of 
ACPA in serum was determined by [CONTACT_791412]. Patients who had serum 
ACPA>20 units were considered positive (CCP+). Based on whether patients were ACPA+, ACPA -, 
CCP+ and CCP - patients were divided into 3 groups:  (i) ACPA+/CCP+ (n=28 eyes). These patients 
had ACPAs in tear fluid as well as serum; (ii) ACPA+/CCP - (n=145 eyes). These patients had ACPAs in 
tear fluid but not in serum; and (iii) ACPA -/CCP - (n=149 eyes). These patients did not have ACPA in 
tear flui d as well as in serum. Patients with ACPA+/CCP+ had the highest levels of ACPA in tear fluid 
as well as in serum compared to other groups. Eyes in ACPA+/CCP+ group had more severe signs and 
symptoms of DED as compared to other groups. These eyes had more severe tear deficiency 
(Schirmer I) and more severe ocular surface disease (corneal staining and conjunctival staining). These 
eyes also had more corneal complications (ulcers, melts or scars). Taken together, these data show 
that patients who have ACPAs in the tear fluid  have more severe signs of DED.   
 -- 
  
  
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
  
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 17 of 59 
 
17 
 
 
Figure 5. Photographs of eyes of Sjogrens syndrome patients with DED and high ACPA levels in 
tear fluid showing severe corneal disease.  (A) 76 year old female with Sjogrens syndrome showing 
a corneal perforation. Serum ACPA level was high (137 units) and tear ACPA levels were also very 
high (145.9 units) in the eye with perforation. In the fellow eye, the ACPA levels were lower (55.8 units). 
(B) A 38 year old female with Sjogrens syndrome showing a corneal scar following sterile ulceration. 
Serum ACPA level was high (216 units) and tear ACPA levels in both eyes were also very high (121.8 
units in the right eye and 142.6 units in the left eye). (C) A 50 year old female with Sjogrens syndrome 
showing a corneal melt resulting in a corneal divot. Serum ACPA level was high (117 units) and tear 
ACPA levels in both eyes were also very high. (D) A 64 year old female with Sjogrens syndrome 
showing severe ocular surface disease as evidenced by [CONTACT_791413][INVESTIGATOR_15424]. Serum ACPA level was high (160 units) and tear ACPA levels in both eyes were 
also very high (153.6 units in both eyes. Taken together, these four cases demonstrate that very 
high levels of ACPA in tear fluid is associated with severe ocular surface disease.   
1.5 Dry Eye Disease: Diagnostic Testing  
 
Clinicians use several diagnostic tests to diagnose DED and to assess disease severity. These tests 
fall into two groups: signs (objective) and symptoms (subjective). For  DED signs, there are several 
quantitative tests, including: Schirmer Test, Schirmer I Test, Schirmer II test, tear film breakup time (TBUT), non -invasive tear film breakup time (NITBUT) epi[INVESTIGATOR_677731] (rose bengal, lissamine 
green, fluorescein) via slit -lamp examination, tear function index (TFI), tear fluid protein immunoassays, 
fluorophotometry, meibography, meibometry, meiboscopy, meniscometry, lacrimal gland biopsy, impression cytology, hypolysozyme measurement, hyperosmolarity measurement,  and lipid layer 
analysis, ocular redness scoring, automated blink analysis, and meniscus evaluation utilizing Lipi[INVESTIGATOR_677732], Keratograph 5M, or OCT equipment.
4  
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 18 of 59 
 
18 
 Symptom measurements utilizing physician and/or patient disease scoring include: extensive 
dry e ye questionnaire (DEQ), visual analog scale (VAS), ocular surface disease index (OSDI), national 
eye institute visual function questionnaire (NEI -VFQ-25), symptom assessment in dry eye questionnaire 
(SANDE), and standardized patient evaluation of eye dryness questionnaire (SPEED) .19, [ADDRESS_1091193] been used in recent DED studies. In this feasibility study, there 
will be multiple exploratory endpoints based on conventional dry eye assessments, subjective 
and objective  (section 2.4) . Based on the results of this study, w e will  decide which sign and/or 
symptom to be used as the primary (or co -primary) endpoint(s) in later stage studies.  
1.6 Dry Eye Disease: Current Management  
 
Typi[INVESTIGATOR_897], clinicians prescribe artificial tear eyedrops and topi[INVESTIGATOR_791360] -term relief of 
DED. Antibiotics (tetracyclines and macrolides), non- steroidal anti -inflammatory agents, autologous 
serum drops, omega fatty acids, mucin secretagogues, and anti -inflammatory agents are also used to 
combat DED symptoms. In addition, prosthetic scleral lenses (i.e. PROSE) that also serve as 
supplemental tear reservoirs are increasingly being prescribed to enhance ocular surface hydration in 
patients with chronic DED. Hot eyelid compresses are often utilized to treat m eibomian gland 
dysfunction, a primary driver of evaporative dry eye disease. In advanced cases of DED, punctual plugs 
can be installed to block tear drainage. In severe cases of dry eye, tarsorrhaphy surgery, tear duct 
cauterization, or amniotic membrane transplant might be required to reduce tear evaporation .4, 21 
Currently there are only two pharmaceutical agents that are FDA approved for the treatment of 
dry eye: cylcosporine an ophthalmic emulsion (Restasis®) and lifitegrast ophthalmic solution (Xiidra™ ). 
Restasis® 0.05% is a topi[INVESTIGATOR_791361] (Restasis® Prescribing Information). Xiidra™ 5% is a lymphocyte function-
associated antigen (LFA -1) antagonist indicated for the treatment of signs and symptoms of dry eye 
disease (Xiidra™ Prescribing Information). Given the complexity, severity, and frequency of DED, and 
given the limited mo des of action by [CONTACT_677769], there is a medical 
need for other dry eye therapi[INVESTIGATOR_014], particularly those with multiple modes of action that target the wider dry eye population and are effective and safe for long- term daily use. 
1.7 Scientific Rationale for IVIG eye drops  in Dry Eye Disease  
 
There is considerable scientific rationale to establish a medically plausible basis for the use of IVIG eye 
drops  for the treatment of DED . It is well established that autoimmune processes  underpin  ocular 
surface  inflammation in DED. For example, B cell over -activation is a key feature of Sjogren’s 
syndrome (a major cause of DED), attested by [CONTACT_791414] (e.g. antinuclear antibodies, anti -Ro/SSA, ant i-La/SSB, rheumatoid factor).
[ADDRESS_1091194] shown that  autoantibodies are present in the tears of DED patients  (Figures 3 & 4) that may 
contribute to ocular surface disease and inflammation  (Table 1) . IVIG has an immunomodulatory 
activity that is based on the modulation of biological processes  that are implicated in innate or acquired 
immunity , therefore it has the potential to reduce autoimmune- mediated inflammation in DED .  
 
To date, IVIG has  not been applied to the ocular surface as eye drops. However, IVIG has been 
administered by [CONTACT_791415] (OCP) and several intraocular inflammatory diseases like birdshot retinochoroidopathy.
23-25 Our data 
shows that the levels of IgG in the tear fluid increase approximately 3 folds after intravenous administration of IVIG to treat OCP  (Figure 13) . 
We posit that topi[INVESTIGATOR_791356] -eye drops will 
achieve significantly higher levels of IgG over the ocular surface as compared to  intravenous 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- [ADDRESS_1091195] shown in conjunctival impression cytology data that the receptors for autoantibodies (Fc 
gamma 1 receptor) are present on the cells (dendritic cells and neutrophils) in the superficial layers of 
the ocular surface, therefore these receptors are accessible to IVIG eye drops for exerting a t herapeutic 
action (Figures 6 & 7 ).  Pooled normal polyspecific human IgG (IVIG) contain antiidiotypic antibodies 
against human autoantibodies may provide a mechanism for the suppressive effect of IVIG in human autoimmune diseases.  Whereas pooled IgG from a high number of normal individuals express 
antiidiotypic antibodies directed against autoantibodies, antiidiotypic antibodies are rarely found in IgG prepared from individual normal donors.
26, [ADDRESS_1091196] antiidiotypic antibodies.  
 IVIG preparation contain pooled polyspecific IgG.  Therefore,  IVIG eye drops will increase the amount of 
IgG on the ocular surface.  This is no different that applying serum tear eye drops to the ocular surface as serum contains IgG (approximately 10 mg/ml). In fact, applying IVIG eye drops 0.4% places 4 mg/ml 
IgG on the ocular surface, which is the identical amount of IgG placed on the ocular surface when using 
50% serum tear eye drops. 50% serum tear eye drops have been used to treat a variety of ocular surface diseases and their use is widely accepted as a useful therapeutic strategy for severe ocular 
surface disease. Although autologous serum tears are more commonly used, there are several reports 
of use of allogeneic serum tears as well. 
We posit that use of IVIG 4 mg/ml will pose no more safety 
risk than that with use of 50% allogeneic serum tears that are already in clinical use.   
 The immunomodulatory biological effects of IVIG  that may reduce the deleterious effects of 
autoantibodies in tear fluid include:  
 A. Functional Blockade of Fc Receptors
. We have performed impression cytology of ocular surface in 
DED patients and found Fc receptor expressing neutrophils and mononuclear cells amongst ocular 
surface cells  (Figure 6) . We also found that IgG interacts with Fc gamma receptors that are expressed 
on neutrophils and dendritic cells on the ocular surface in DED patients (Figure 7 ). These IgG are likely 
to be autoantibodies.   Blockade o f Fc receptors  by [CONTACT_791416]- eye drops  may reduce the interaction of 
autoantibodies with Fc receptors, thus reducing the deleterious effects of autoantibodies  on the ocular 
surface.  
 
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 20 of 59 
 
20 
 
 
Figure 6: Immunofluorescence staining of Fc gamma 1 receptors and ocular surface cells in 
conjunctival impression cytology specimen obtained from patient with DED due to Sjogren’s 
Syndrome.  Since immunoglobulins (monomeric IgG or immune complexed IgG) bind to Fc gamma 1 
receptors to propagate the immune response, the presence of Fc gamma receptors on ocular surface 
cells is a prerequisite for induction of an immune response. Therefore, we performed conjunctival 
impression cytology on Sjogren’s Syndrome patients to determine whether Fc gamma 1 receptors 
(CD64 positive) are present on conjunctival epi[INVESTIGATOR_1663] (K14 positive) and bone marrow derived 
dendritic cells (CD11c positive) or neutrophils (neutrophils elastase positive) that are also present on 
the ocular surface. Impression filter papers were processed for immunofluorescence staining with anti -
CD64 antibody (mouse monoclonal anti -CD64 antibody; Santa Cruz, #sc -1184, 1:500), anti -K14 
antibody (rabbit polyclonal anti -cytokeratin 14 antibody; BioLegend, #905301, 1:1000), anti -CD11c 
antibody (rabbit monoclonal anti CD11c  antibody; Abcam, #ab52632, 1:500), and anti -neutrophil 
elastase antibody (rabbit polyclonal anti neutrophil elastase antibody; Abcam, #ab21595, 1:500). Figure 
6A2 shows expression of Fc gamma receptors (red) and figure 6A3 shows conjunctival epi[INVESTIGATOR_1663] 
(green). Figure 6A4 shows that Fc receptors and conjunctival epi[INVESTIGATOR_791362]- localize. 
Therefore, Fc gamma receptors are expressed on non- epi[INVESTIGATOR_791363]. Figure 6B2 
shows expression of Fc gamma receptors (red) and figure 6B3 shows dendritic cells (green). Figure 
6B4 shows co- localization of Fc gamma receptors on dendritic cells. Therefore, Fc gamma receptors 
are expressed on bone- marrow derived dendritic cells. Figure 6C2 shows expression of Fc gamma 
receptors (red) and figure 6C3 shows neutrophils (green). Figure 6C4 shows co- localization of Fc 
gamma receptors on neutrophils. Since neutrophils express Fc gamma receptors only when activated, 
expression of these receptors on neutrophils on the ocular surface suggests that these neutrophils are 
in an activated state. Taken together, figure 6 data shows that Fc gamma receptors (effectors for 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 21 of 59 
 
21 
 immunoglobulin induced immune reaction) are not expressed on conjunctival epi[INVESTIGATOR_791364]- marrow derived dendritic cells and neutrophils present on the ocular 
surface.  
 
 
Figure 7 : Immunofluorescence staining to demonstrate the interaction between 
immunoglobulins (IgG) and Fc gamma 1 receptors on ocular surface cells in conjunctival 
impression cytology specimen obtained from patient with DED due to Sjogren’s Syndrome.  
Since immunoglobulins bind to Fc gamma 1 receptors to propagate the immune response, the binding 
of IgG to Fc gamma receptors on ocular surface cells is a prerequisite for induction of an immune 
response.  Therefore, we performed conjunctival impression cytology on Sjogren’s Syndrome patients to 
determine whether IgG and Fc gamma 1 receptors (CD64 positive) co -localize and to determine which 
ocular surface cells bind to IgG. Impression filter papers  were processed for immunofluorescence 
staining with anti- CD64 antibody (mouse monoclonal anti -CD64 antibody; Santa Cruz, #sc -1184, 
1:500),anti -neutrophil elastase antibody (mouse monoclonal anti -neutrophil elastase antibody; Santa 
Cruz, #sc -[ZIP_CODE], 1:500),  anti-CD11c antibody (mouse monoclonal anti CD11c antibody; BD 
biosciences, #565805, 1:100) and anti -IgG antibody (rabbit monoclonal anti human IgG antibody; 
Abcam, #ab109489, 1:500) and confocal immunofluorescence microscopy was performed to localize 
the proteins. Figure 7A2 shows expression of Fc gamma receptors (red) and figure 7A3 shows IgG 
presence (green). Figure 7A4 shows that IgG co- localizes with Fc gamma 1 receptors, suggesting IgG -
Fc gamma receptor interaction. Figure 7B2 shows presence of neutrophils (neutrophil elastase positive, 
red) and figure 7B4 shows these neutrophils co- localize with IgG. Figure 7C2 shows presence of bone-
marrow derived dendritic cells (CD11c positive, red) and figure 7C4 shows these dendritic cells co -
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 22 of 59 
 
22 
 localize with IgG. T aken together, figure 7 data shows that IgG interacts with Fc gamma receptors 
that are expressed on neutrophils and dendritic cells that are present on the ocular surface in 
DED patients in Sjogren’s Syndrome.  
B. Autoantibody Neutralization and Inhibition of Autoantibody Production . IVIG preparations contain 
anti-idiotypic antibodies, i.e., antibodies that are able to interact  specifically with the variable region 
(antigen recognition site) of autoantibodies. This interaction has the potential to neutralize an 
autoantibody and to hamper its production via binding to auto  reactive B lymphocytes. Suc h a 
neutralizing or inhibitory activity has been shown, amongst others, for  autoantibodies directed against 
factor VIII, DNA, intrinsic factor, thyroglobulin and anti-neutrophil cytoplasmic antibodies (ANCA) . We 
have found the presence of  anti-citrullinated protein antibodies (ACPAs) in the tear fluid of DED 
patients (Figure 3).  Anti-idiotypic antibodies in IVIG -eye drops may neutralize ACPAs in the tear fluid of 
DED patients to reduce ACPA- induced ocular surface disease.  
 
C. Other Mechanisms:  (i). Complement Inhibition. The Fc portion of IVIG can bind the C3b and C4b 
fragments of complement, and thereby [CONTACT_791417] t he C5 
convertase (C4b2a3b), hampering the subsequent formation of the membrane attack complex. This 
cascade of events has been shown to occur in dermatomyositis and thereby [CONTACT_791418].  (ii). Modulation of Cytokine and Cytokine Antagonist 
Production. IVIG may significantly modulate the production of several cytoki nes (including IL- 1,-2,-3,-4,-
5,-10, TNF-alpha , and GM -CSF) and cytokine antagonists (IL- [ADDRESS_1091197]) by  [CONTACT_791419]-
macrophages and lymphoc ytes. (iii). Modulation of Dendritic Cell Properties. Recent work suggests that 
IVIG also affects the differentiation, maturation and functional status of dendritic cells (DCs). DCs 
appear to be a primary target for the immunosuppressive effects of IVIG on T- cell activation. (iv). 
Signaling through the Inhibitory Fc Receptor, Fcgamma RIIB . (v). Expansion of regulatory T cells and 
reciprocal inhibition of Th17 cells . 
1.8 Specific Agent  in this Study  
 
The primary agent used in this study is a commercial Intravenous immunoglobulins (IVIG ) formulation 
(Flebogamma DIF 5%) that will be diluted in 0.9% saline to achieve 4 mg/ml  (0.4%)  IgG concentration, 
and dispensed as eye drops . Intravenous immunoglobulins (IVIG ) are a therapeutic preparation of 
pooled normal human IgGs obtained from large numbers of healthy donors. 
 
Flebogamma DIF 5% IVIG is an FDA -approved product available as 50 mg/ml an immune globulin 
intravenous (human) solution indicated in adults and pediatric patients 2 years of age and older for the treatmen t of primary immunodeficiency (PI), including the humoral immune defects in common variable 
immunodeficiency, x -linked agammaglobulinemia, severe combined immunodeficiency, and Wiskott -
Aldrich syndrome. It is stable at room temperature for more than two years.   
Flebogamma 5% DIF contains 5 g human normal immunoglobulin and 5 g D -sorbitol (as stabilizer) in 
100 m L of water for injection, and ≤ 3 mg/mL polyethylene glycol. There is no preservative in the 
formulation. The pH of the solution ranges from 5 to 6 and the osmolality from 240 to 370 mOsm/L, 
which is within the normal physiological range.  
 
From a safety perspective, IVIG eye drops would most closely resemble allogeneic unfractionated 
blood eye drops  (serum or plasma) . From an efficacy perspective, IVIG eye drops have the potential to 
significantly improve outcomes of autoimmune and inflammatory ocular surface disease, given the long shelf life at room temperature making storage & dispensing by [CONTACT_791420].  
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 23 of 59 
 
23 
 IgG at 4 mg/ml  (0.4%)  concentration (in the form of serum/plasma 50% eye drops) is routinely used to 
treat ocular surface diseases, however widespread use is limited because of short shelf life and limited 
number of  blood processing compounding pharmacies. We propose to use IgG at a similar 4 mg/ml  
(0.4%)  concentration (in the form of IVIG eye drops) to treat ocular surface diseases as this strateg y 
offers significant advantages, chief amongst which is a long shelf life at room temperature that makes 
widespread dispensing possible.  
1.[ADDRESS_1091198] performed in vitro  studies using cultured human epi[INVESTIGATOR_791365] (4 mg/ml) causes cytotoxicity. Our data shows that IVIG 4 mg/mL does not induce cytotoxicity in 
cultured corneal epi[INVESTIGATOR_1663] (Figure 8 ).  
 
We have performed in vivo  studies to determine whether IVIG -eye drop (4 mg/mL) causes ocular 
surface toxicit y when applied to murine corneas. Our data shows that there was no difference in 
corneal fluorescein staining between IVIG group and the control group. This suggests that topi[INVESTIGATOR_791366] (4 mg/mL) does not cause ocular surface toxicity  (Figure 9) . 
 
 
Figure 8: Wound scratch assay and LDH cytotoxicity assay in cultured human corneal epi[INVESTIGATOR_15129] (primary and immortalized).  These experiments were performed to determine whether IVIG 
causes cytotoxicity in cultured human corneal epi[INVESTIGATOR_265731].  Human corneal epi[INVESTIGATOR_791367] (serum) or stressed (serum free) conditions with or without incubation with IVIG 
(4 mg/mL or 10 mg/mL) in IncuCyte® S3 Live Cell Analysis System (Essen Biosciences). IVIG toxicity 
was ass essed using the LDH assay kit from Thermo Scientific according to the manufacturer’s 
specification. (A1- A6): Representative IncuCyte images after 69 hours of incubation show that scratch 
wounds in primary human corneal epi[INVESTIGATOR_791368]. (A7) LDH 
cytotoxicity assay shows absence of cytotoxicity with 4 mg/mL IVIG but significant cytotoxicity with 8 
mg/mL IVIG. Representative IncuCyte images after 12 hours of incubation show that scratch wounds in 
immortalized human corneal  epi[INVESTIGATOR_791369] 
(B1-B6) as well as under stressed condition (C1- C6). LDH cytotoxicity assay shows absence of 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 24 of 59 
 
24 
 cytotoxicity with 4 mg/mL IVIG but significant cytotoxicity with 10 mg/mL IVIG under both normal (B7) 
and stressed (C7) cultured conditions. Taken together, these experiments show that IVIG 4 mg/mL 
does not induce cytotoxicity in cultured corneal epi[INVESTIGATOR_1663].    
 
 
Figure 9 : In vivo toxicology study of IVIG application in murine corneas.  These experiments were 
performed to determine whether IVIG -eye drop (4 mg/mL) causes ocular surface toxicity when applied 
to murine corneas. IVIG (10 uL of 4 mg/mL solution) or Refresh Optive (control) was applied once a day 
to the mouse corneas (n=8/gr oup) for [ADDRESS_1091199] time of eye drop with the eye. Fluorescein staining 
was performed at base line and at weekly intervals thereafter. (A1-A8) Representative mouse cornea 
images showing fluorescein staining after incubation with Refresh Optive (control group, A1- A4) and 
IVIG (experimental group, A5- A8). (A9) Graph showing the quantitative data for the fluorescein staining 
at Day 0, 7, 14, 21 and 28. There w as no difference in fluorescein staining between IVIG group 
and the control group. This suggests that topi[INVESTIGATOR_791370] (4 mg/mL) does 
not cause ocular surface toxicity.  
1.[ADDRESS_1091200] increased IgG levels in ocular tissues or serum after applying IVIG as eye 
drops in non- inflamed and inflamed murine eye. The poor penetration of IVIG eye drops in ocular 
tissues may actually be desirable because it further improve its safety profile for use in DED bec ause 
DED is rarely associated with intraocular inflammation, therefore intraocular penetration of drug is not 
needed to treat DED.  
 
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 25 of 59 
 
25 
 Figure 10: Tissue distribution study of IVIG application in naïve and inflamed murine corneas.  
This experiment was performed to determine whether IVIG eye drops applied topi[INVESTIGATOR_791371] (cornea, conjunctiva, retina and lacrimal gland) in a naïve (A1 -A5) or inflamed (B1 -B5) eye.  
Experiment 1  (Naïve eyes):  Refresh Optive + IVIG (4 mg/mL) were applied to murine  corneas 
(n=6/group) once a day for six consecutive days. Control eyes received Refresh Optive only. 
Experiment 2 ( Inflamed eyes):  Benzalkonium chloride (BAK, 0.1%) + IVIG (4 mg/mL) were applied to 
the murine corneas (n=6/group) once a day for six consecutive days. Control eyes received BAK 
(0.1%) only. In both experiments,  after each application, the mice were restrained for [ADDRESS_1091201] time of eye drop with the eye. After 6 days, the samples (cornea, conjunctiva, 
retina, extraor bital lacrimal gland and serum)  were collected, normalized to protein amount, and 
processed for Luminex detection of Human IgG (name [CONTACT_791458]). (A1- A5): Graphs show human 
immunoglobulin isotypes collected from tissues in experiment 1 (naïve eyes). (B1- B5): Graphs show 
human immunoglobulin isotypes collected from tissues in experiment 2 (inflamed eyes). No tissue or 
serum showed a significant increase or decrease in human IgG amount. Taken together, these 
experiments show that topi[INVESTIGATOR_791372].   
1.11 IVIG Animal Efficacy and Clinical Data to Date  
1.11.1  IVIG Animal Efficacy Data  
 
 
 
Figure 11 : In vivo  efficacy study of IVIG -eye drop to treat corneal inflammation induced by 
[CONTACT_791421] (BAK).  These experiments were performed to determine whether IVIG- eye 
drop (4 mg/mL) reduces ocular surface inflammation in murine corneas. In the control groups, IVIG (4 
mg/mL) only or BAK (0.1%) only were applied to murine corneas (n=6/group) once a day for 6 
consecutive days to induce corneal inflammation. In the experimental group, BAK (0.1%) and IVIG (4 
mg/mL) were applied to the murine corneas (n=6) once a day for [ADDRESS_1091202] time of eye drop with 
the eye. Fluorescein staining was performed at base line and every other day. (A1- A3): Representative 
mouse cornea images showing no increased in fluorescein staining in control group IVIG (4 mg/mL) 
only. Compared to BAK only g roup (A4- A6), IVIG and BAK group (A7- A9) showed significantly less 
corneal staining at Day 3 and Day 6. Corneas in BAK only group and IVIG + BAK group had epi[INVESTIGATOR_268992]. We compared the area of epi[INVESTIGATOR_17754] (A10) and the number of eyes (%) that had corneal 
epi[INVESTIGATOR_17754] (A11) between BAK only group and IVIG + BAK group. In the IVIG + BAK group, the 
corneal epi[INVESTIGATOR_791373] (A10) and the percentage of 
eyes with corneal epi[INVESTIGATOR_791374] (A11). Taken together, these data show 
that IVIG application to the eye reduces corneal inflammation.   
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 26 of 59 
 
26 
  
 
 
Figure 12: In vivo  efficacy  study to determine the therapeutic potential of blocking the 
interaction of Anti -Citrullinated Protein Antibody (ACPA) with Fc receptors on murine corneas.  
These experiments were performed to determine whether strategies to block ACPA -Fc receptor 
interaction (using either IgG for competitive blocking or peptides for Fc receptor blocking) abrogate 
ACPA-i nduced ocular surface disease.  Citrullinated Histone H4 antibody (H4R3 ACPA, 100 ng/mL) was 
applied to the mouse cornea to produce ocular surface disease. Mouse IgG (100 ng/mL) was used for 
competitive blocking (Experiment 1) and a peptide (1:40 dilution) was used for Fc receptor blocking 
(Experiment 2). Experiment 1 : In control group, H4R3 ACPA (10 uL solution) only was applied over the 
ocular surface of anesthetized mice for 40 minutes once a day for 7- 8 consecutive days. In 
experimental group, H4R3 ACPA + mouse IgG was applied in identical amount and time as the control 
group. Ocular surface disease was assessed with fluorescein staining. Representative mouse cornea 
images showing fluorescein staining after incubation with H4R3 ACPA solution only (A1- A2) and H4R3 
ACPA + mouse IgG solution (A3 -A4). Fluorescein staining of corneas in H4R3 ACPA + mouse IgG 
group was significantly lower than H4R3 ACPA group alone (A5). Experiment 2 : In control group, a 
scrambled peptide (10 uL) was applied to the eye of an unanasthetized mice. After the application, the 
mice were restrained for [ADDRESS_1091203] time of eye drop with the eye. 30 
minutes after control peptide application, H4R3 ACPA (10 uL solution) was applied over the ocular 
surface of anesthetized mice for 40 minutes. In the experimental group,  azide- free Fc receptor blocker 
(Innovex Biosciences # NB355)  (10 uL) and H4R3 ACPA were applied to mouse eye in a manner 
identical to the control group. Representative mouse cornea images showing fluorescein staining after 
incubation with control peptide + H4R3 ACPA (B1- B2) and Fc receptor blocking peptide + H4R3 ACPA 
(B3-B4). Fluorescein staining of corneas in Fc receptor blocking peptide + H4R3 ACPA group was 
significantly lower than control peptide + H4R3 ACPA (B5). Taken together, these experiments show 
that blocking the interaction of ACPA with Fc receptors reduces ocular surface disease. 
Therefore, using IVIG eye drops may have therapeutic potential via this mechanism.    
1.11.[ADDRESS_1091204] , sufficient 
clinical data is available regarding  systemic administration  of IVIG for treating ocular surface diseases . 
IVIG therapy (given via intravenous route)  has been used to treat Mucous Membrane Pemphigoid 
(MMP), a severe ocular surface disease, in patients who do not respond to conventional therapy or 
stopped using them for various side effects. A review of literature identified [ADDRESS_1091205] 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- [ADDRESS_1091206] a similar safety 
profile.   
 
Immunoglobulins ( IgG) have been placed on the ocular surface in the form of autologous/allogeneic 
serum/plasma eye drops for treating ocular surface diseases . Blood derived products (unfractionated 
serum or plasma eye drops) are essentially physiological IgG formulations, therefore clinical data 
pertaining to their use  in treating ocular surface diseases is relevant to the proposed fractionated 
plasma product (IVIG eye drops ). This is because the IgG concentration in unfractionated 
serum/plasma eye drops  (50%) and the proposed IVIG eye drops is similar (4 mg/ml).  Normal average 
serum IgG values are 10 mg/ml.11, 29 Serum  also contains important nutritive elements (such as  vitamin 
A, epi[INVESTIGATOR_5169], transforming growth factor -β, fibronectin, nerve growth factor and insulin-
like growth factor) that promote the viability of ocular surface cells.30-34 Serum can be formulated as 
autologous or allogeneic serum tear eye drops in specialized laboratories or compounding pharmacies. 
Autologous serum drops are produced from the patient’s own peripheral blood, wher eas Allogeneic 
serum drops made from voluntary donors.35, [ADDRESS_1091207]. Allogeneic 
serum may be an appropriate alternative for selected patients who would benefit from serum treatment 
but whose autologous serum is unavailable or unsuitable.52, 57- 60  
 Limitations of Serum eye drops: One important practical limitation in treatment with serum eye drops 
is the very short shelf life. The [LOCATION_002] Pharmacopeia standard recommends a [ADDRESS_1091208] to be 
kept refrigerated at 4 C and they expi[INVESTIGATOR_352743] 3 days. Other practical issues are that only a 
compounding pharmacy can prepare the eye drops and serum eye drops lack insurance coverage.  
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 28 of 59 
 
28 
 
 
Figure 13:  IgG levels in tear fluid after intravenous administration of IVIG to treat DED in a 
patient with ocular cicatricial pemphigoid (OCP). We determined whether IgG levels in tear fluid 
increase after IVIG is administered by [CONTACT_100305].  A 39 year old male had severe symptoms 
of ocular discomfort and severe tear deficient DED due to OCP. A decision was made to treat him with 
intravenous IVIG. Flebogamma 5% 60g/1200 mL IV per protocol was administered. Tear fluid was 
collected prior to IVIG infusion and following IVIG infusion and analyzed for total amount of IgG using 
Human Immunoglobulin Isotypi[INVESTIGATOR_791358] (Cat. No. HGAMMAG -301K, EMD Millipore, 
Billerica, MA).. At day [ADDRESS_1091209] IVIG infusion, IgG level in tear fluid showed 4.8 fold 
increase in right eye and 4.7 fold increase in left eye. Taken together, these data showed that IgG 
levels in tear fluid increases several fold after intravenous IVIG administration.  
1.12 Dose Rationale and Risk/Benefits  
 
Prop osed dose:  IVIG eye drops 4 mg/ml  (0.4%)  two times a day.   
 Rationale:
 Serum eye drops, compounded by [CONTACT_791422] 50% in normal saline, are routinely 
used for treating ocular surface diseases. The amount of IgG in undiluted serum is approximately 10 mg/ml, therefore 50% serum eye drops has approximately 5 mg/ml IgG, and serum eye drops are generally used four times a day. Since, at 50% dilution serum eye drops are effective in treating ocular 
surface diseases, we have proposed a similar dose of IgG in IVIG eye drops (4 mg/ml). In our in vitro 
experiments, we have determined 4 mg/ml IVIG to be non- toxic, as this dose, when added to medium 
of cultured epi[INVESTIGATOR_475592] [ADDRESS_1091210] estimated IgG amount on the ocular surface to be approximately 0.5 mg/ml, therefore the IVIG dose should be at least 
2 mg/ml to be effective. Taken together, our proposed dose of IVIG eye drops replicates the clinically 
in-use dose of IgG in serum tears, is non- toxic in vitro, and above the threshold required to be effective.  
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 29 of 59 
 
29 
 Adverse Effects of IVIG Treatment:  To date, IVIG has been administered via systemic route only. Mild 
to moderate adverse reactions to high -dose IVIG therapy might  be seen in nearly 30% of patients . 
Some of the common  adverse reactions include fever, headache, chills, nausea,  hypotension, and 
muscle cramps. Temporary cessation of  the IVIG infu sion, slow infusion, and use of general anti -
inflammatory agents can control these events. Switching to SCIG is another viable alternative. 
Anaphylaxis can occur  in IgA -deficient patients and use of low IgA -containing IVIG preparations is 
recommended in such cases.  Other effects include meningeal inflammation and aseptic  meningitis due 
to the release of inflammatory cytokines and  neutrophil activation by [CONTACT_791423]; intravascular hemolysis due to  the presence of anti -A or anti -B 
isoagglutinins or less commonly  anti-D or anti -K Abs; thromboembolism because of  contamination of 
IVIG with clotting factors and formation of  platelet -leukocyte aggregates; and renal complications due to  
osmotic injury that could be prevented by [CONTACT_216138]– sugarstabilized IVIG.  
 
Possible contamination of IVIG with infectious agents like  viruses and prions always exists. However, 
viral inactivation  steps, caprylation, and nanofiltration aid in the safety profile of  IVIG.  
2 Study Objectives  
 
The main objective of this study is to establish whether patients with Dry Eye Disease  are able to safely 
tolerate receiving Intravenous Immunoglobulin (IVIG) eye drops two times a day for eight weeks 
(primary ‘safety and tolerability ’ objective) . The exploratory  objective is to investigate the preliminary 
efficacy of the use of IVIG eye drops  in treating Dry Eye Disease  (exploratory  efficacy objective)  to 
estimate the  effectiveness of the trial intervention and collecting data to inform the design of a future 
definitive trial. 
3 Study Design  
3.1 General Design  
 
This will be a Randomized controlled trial, in which a total of 28 subjects  will be enrolled at 1 clinical 
site. Subjects will be randomly assigned to one of two groups  (#1, #2) , with 14 subjects per group. One 
group will be given placebo (Normal saline eye drops ) and the other group will be given eye drops 
containing the study drug ( IVIG).  
 
Patients with established Dry Eye Disease  will be approached by a member of the research staff to 
determine if he/ she might be interested in participating in a research study. If the subject  is interested, 
the research staff member will describe the study. If the subject is willin g to enter the study, the study 
will be discussed and the subject  will be asked to sign the informed consent form. Consent will be 
obtained prior to screening to determine eligibility. Screening procedures include documentation of Dry 
Eye Disease. Eligible  subjects  will be enrolled in the study.  
 
All enrolled subjects will receive their first dose of test medication (placebo/ study drug)  on study Day 1 
in the doctor’s office, and after completion of the study assessments , will have the topi[INVESTIGATOR_791375] -administration.  See Section 5.[ADDRESS_1091211] 
any adverse symptoms. In addition, they will be asked to make a note of any missed doses together with the reason for the omission. Subjects will return at 4 weeks  for further study assessments, 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 30 of 59 
 
30 
 thereafter at 8 weeks (the last day of treatment), and again at [ADDRESS_1091212] substance tolerance between Day 1 (post -
dose) and 8 weeks (56 days).  
3.2 Tolerability End Point: Test Substance Tolerance (Visual Analogue Scale)  
 
Subjects will assess their tolerance to the administration of the test medication (placebo/ study drug), 
utilizing a Visual A nalog Scale (VAS) . The VAS is a horizontal line with verbal descriptors at either end. 
The VAS ratings will be completed after administration of the test medication on Day 1 (post -dose), 
week [ADDRESS_1091213] a single slash mark across the horizontal line between the end 
labeled “completely intolerable” (0 mm) and “easily tolerable” (100mm). The VAS rating is as follows:  
 
Please rate the degree of comfort or lack of comfort associated with administering the eye drop by 
[CONTACT_791424]:  
 
      
 
 
 
 
 
  
3.3 Secondary Study Endpoint  
 
There are no secondary endpoints in this study.  
3.4 Exploratory  Study Endpoints   
The exploratory  study endpoints will include:  
1. The change in the Ocular Surface Disease Index (OSDI) which is a patient ’s subjective r ating 
scale 
2. Change in tear secretion as measured by [CONTACT_80688] I test  
3. The proportion of eyes achieving complete corneal staining clearance after  treatment  
4. Change in corneal  staining score as measured by [CONTACT_791425] [ADDRESS_1091214] drug.  
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 31 of 59 
 
31 
 5. The change in subjective ocular surface redness score (OR) using the validated bulbar redness 
(VBR) grading scale  
6. Visual acuity change  
7. Change in frequency of administration of artificial tears or concomitant eye drops  
8. Change in number of corneal filaments (slit -lamp examination)  
9. Change i n amount of mucoid films  (slit-lamp examination)  
10. Clinical Global Impression (CGI) of change in symptoms  from baseline (physician’s rating)  
11. Subject Global Assessment (SGA) of overall change from baseline ( subject ’s rating)  
12. Change in Non- Invasive Keratograph  Tear Break -Up Time (NIKBUT)  
13. Change in Keratograph Ocular Bulbar Redness Score  
14. Change in MMP -9 Protein Detection 
15. Change in amount of Cytokines in ocular surface wash  
3.4.1  Exploratory Efficacy End Point: Ocular surface Lissamine  Dye staining score  
 
Ocular surface staining will be assessed using Lissamine Green Dye for Cornea and C onjunctiva. The 
scoring pattern is represented below.  
  
Lissamine Green Dye Staining for Cornea and Conjunctiva: 
 
Using 5uL fixed pi[INVESTIGATOR_791376] a 10uL pi[INVESTIGATOR_714740] 5uL of the Lissamine will  be drawn from the Eppendorf 
vial and after slightly pulling the eye lid of the patient Lissamine dye will be released over the ocular surface of both eyes. Using the slit lamp nasal -bulbar and temporal- bulbar conjunctiva will be graded 
within 2 minutes for each eye.   
 
 
 
  
 
Corneal staining will be graded in 5 zones . Each zone will be graded from 0 to 3 based on the density 
of punctate staining.  
  
  
 
 
 
 
  
3.4.2  Exploratory Efficacy End Point: Ocular Surface Disease Index (OSDI)  
 
The OSDI rating scale  has twelve questions in three discrete areas, with responses rated on a five 
point scale.  Subjects will complete this scale on Day [ADDRESS_1091215] dose  (Baseline) , week  4, week  8 and 
week  10. The questions and scoring system are shown below : 61 
 
 
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- [ADDRESS_1091216] WEEK:  
 
 All of the 
time Most of 
the time  Half of 
the time  Some of 
the time  None of 
the time  
1. Eyes that are sensitive to 
light?  4 3 2 1 0 
2. Eyes that feel gritty?  4 3 2 1 0 
3. Painful or sore eyes?  4 3 2 1 0 
4. Blurred Vision?  4 3 2 1 0 
5. Poor vision?  [ADDRESS_1091217] WEEK:   
 All of 
the time  Most of 
the time  Half of 
the time  Some 
of the 
time None of 
the time   
6. Readin g? 4 3 2 1 0 N/A 
7. Driving at night?  4 3 2 1 0 N/A 
8. Working with a 
computer Or bank 
machine (ATM)?  4 3 2 1 0 N/A 
9. Watching TV?  4 3 2 1 0 N/A 
 
HAVE YOUR EYES FELT UNCOMFORTABLE IN ANY OF THE FOLLOWING SITUATIONS DURING 
THE LAST WEEK:  
 
 All of 
the time  Most of 
the time  Half of 
the time  Some 
of the 
time None of 
the time   
10. Windy conditions?  4 3 2 1 0 N/A 
11. Places or areas with 
Low humidity (very 
dry)?  4 3 2 1 0 N/A 
12. Areas that are air 
conditioned?  4 3 2 1 0 N/A 
 
3.4.3  Exploratory Efficacy End Point: Clinical Global Impression (CGI)  
 
At each visit, the physician (Principal Investigator) will use his clinical evaluation (all signs and 
symptoms taken together) to provide a global assessment of the subjects ’ change in symptoms and 
signs. The CGI is a follows:  62  
 
Question (to physician):  In general, compared with the subjects ’ symptoms and signs at baseline, 
how would you characterize his/ her overall signs and symptoms now? 
 
The responses will be categorized on a seven point scale as follows:  
 
 Marked worsening 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 33 of 59 
 
33 
 Moderate worsening  
Minimal worsening  
Unchanged  
Minimal improvement  
Moderate improvement  
Marked improvement  
3.4.4  Exploratory Efficacy End Point: Subject Global Assessment (SGA)  
 
At each visit, the subjects will be asked to assess their overall change from baseline. The S GA is as 
follows:  62 
Question 1 (to subject):  Compared with your first visit, how are your eye symptoms now?  
 
The responses will be categorized on a five point scale as follows:   
Much worse Worse 
About the same  
Improved 
Much improved  
 
Question 2 (to subjec t): Compared with your first visit, how is the mucous strings or mucous 
discharge from your eyes now? 
 
The responses will be categorized on a five point scale as follows:  
Much worse Worse 
About the same  
Improved 
Much improved  
3.4.5  Exploratory Efficacy End Point : Ocular surface redness score  
 
Ocular surface redness (nasal or temporal)  will be assessed using the Validated Bulbar Redness 
grading scale (VBR).63 The VBR consists of a set of ten images illustrating different degrees of ocular 
surface redness (OR) , ranging from normal to severe, and each image is assigned a value in an order 
of ascending severity.  Colored copi[INVESTIGATOR_791377].  Subjects will be examined by a slit -lamp and the bulbar conjunctival inj ection of the subject’s 
eye (nasal and temporal) will be compared to the reference  images and graded accordingly.  
 
Photographic anchors and their respective grades for ocular surface redness are shown below:  
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 34 of 59 
 
34 
 
 
 
3.4.6  Exploratory Efficacy End Point: Keratograph Oculus Redness Score  
 
Keratograph is FDA approved and is used in routine clinical care of patients in the US.  The Oculus 
Keratograph 5M performs a non -invasive tear film analysis.  It uses a Placido bowl with a camera 
aperture that has a fixation mark in the center. The device provides consistent illumination, allowing 
scanning of the exposed bulbar conjunctiva to take place. The keratograph then analyzes the scanned 
area. This system generates a BR score automatically, which is based on the area percentage ratio 
between the vessels and the rest of the analyzed area. For instance, if the ratio is 16%, then the score 
is 1.6. The maximum ratio, according to the manufacturer, is 40%; therefore, the BR scores that the 
machine gene rates range between 0.0 and 4.0.  
 
Non-invasive Keratograph Tear Film Break- up Time (NIKBUT)  
 
The non -invasive Keratograph tear film break -up time (NIKBUT) measures tear film stability. The 
NIKBUT is automatically measured within seconds, without fluorescein application. Tear Break -up Time  
(TBUT) will be measured twice for each eye using IR video derived from the Oculus noninvasive 
Keratograph tear breakup time (NIKBUT) tool. Based on the device IR video, the device generates 2 measures for TBUT: NIKBUT -first (time at which the first breakup of tears occurs) and NIKBUT- average 
(average  time of all breakup incidents) automatically and without touching the eye.  
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 35 of 59 
 
35 
 
 
 
3.4.7  Exploratory Efficacy End Point: InflammaDry for MMP -9 Protein  
 
InflammaDry is FDA approved and is used in routine clinical care of  patients in the US. Elevated levels 
of the MMP -9 protein in human tears will be detected visually, qualitatively, and in vitro using 
InflammaDry for MMP -9. InflammaDry will be performed PRIOR to instilling ocular anesthetic, topi[INVESTIGATOR_791378], or performing Schirmer testing. Tear fluid sample will be collected by [CONTACT_791426]’s palpebral conjunctiva. The test is assembled by [CONTACT_791427]. The 
buffer vial is opened and immersed in the absorbent tip. The absorbent tip is removed from the buffer 
vial, the protective cap is replaced, and the test is laid flat on a horizontal surface.The results of the test 
are indicated through two (2) lines, the control line and the result line in the result window.  
 
POSITIVE RESULT:  The presence of both a BLUE line in the control zone and a RED line in the result 
zone indicates a positive result. A positive result indicates the presence of MMP -9 >= 40 ng/ml.  
NEGATIVE RESULT:  The presence of only a BLUE line in the control zone indicates a negative result. 
A negative result is indicative of an MMP -9 < 40 ng/ml.  
INVALID RESULT:  If a BLUE line does not appear, the test may be invalid. Re -immerse the absorbent 
tip into the buffer vial for an additional ten (10) seconds. If a BLUE line still does not appear, the test 
must be discarded and the subject retested by [CONTACT_791428] a new InflammaDry test.  
 
 
3.4.8  Exploratory Efficacy End Point: Symptom  (Ocular Discomfort)  Intensity   
 
Symptom (ocular discomfort) intensity will be assessed utilizing a Visual Analog Scale (VAS). The VAS 
is a horizontal line with verbal descriptor anchors  at regular intervals.  Symptom intensity will be 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 36 of 59 
 
36 
 asses sed on baseline, week 4, week 8, and week 10. Subjects will be asked to assess their symptom 
intensity as a fraction of 10.  The symptom intensity  will be assessed as follows:  
Question to the patient : On a scale from [ADDRESS_1091218] 24 hours?  
 
  [ADDRESS_1091219]. 
 
In addition to the prim ary tole rability endpoint (Section 2.2 ), the following safety endpoints will be 
assessed:  
 
• The proportion of screened subjects  who are successfully recruited in the study (i.e., recruitment 
rate) 
• The proportion of eligible subjects at Day 56  who successfully complet e (i.e., retention rate, 
(non)compliance or adherence rate) a full eight weeks (i.e., 56  days) of therapy with topi[INVESTIGATOR_791379] (BID).   
• All reported adverse events, classified by [CONTACT_35043], severity, and relatedness, from baseline 
(Day 1) throu gh the last study visit (Day 70).  
• Clinically significant changes in vital signs or ophthalmic examination from baseline.  
3.5.[ADDRESS_1091220] 
medication (placebo/ study drug)  and week 4, week 8 and week 10. The following vital signs will be 
measured: 1) blood pressure measurements (mm Hg) will be taken while the subject is relaxed in a 
sitting position for at least 3 minutes with the arm  at heart level. 2) Heart rate will be measured via 
auscultation of the heart or palpation of a peripheral pulse and will be recorded in beats per minute (bpm). 3) Oral temperature will be recorded in degrees Fahrenheit (
0F). Subjects with an oral 
temperat ure less  than (≤) 99.60F (37.40C) may continue.  
 
Clinically significant negative changes from baseline will be recorded on the adverse event forms.  
3.5.[ADDRESS_1091221] a complete undilated examination of the eyes using a binocular slit lamp. The Investigator will examine the tear film, eye lids, lashes, bulbar and palpebral conjunctiva, upper and lower lid puncta, cornea, anterior chamber, iris, lens, and anterior vitreous. Specific signs  (if 
they are present)  that w ill be recorded include: lacrimal sac area erythema, swelling or tenderness; 
froth or debris or mucous strands in tear film; eyelid hyperemia; punctal hyperemia or atresia; 
conjunctival/  epi[INVESTIGATOR_791380]; papi[INVESTIGATOR_791381]; chemosis, epi[INVESTIGATOR_791382]; superficial punctate keratopathy, corneal scar, corneal neovascularization;  presence and 

IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 37 of 59 
 
37 
 number of corneal filaments, presence or absence of mucoid films,  anterior chamber cell, flare or KPs; 
pupil shape abnormalities, anterior or posterior synechiae, iris neovascularization; lenticular opacities; 
vitreous cells or pi[INVESTIGATOR_2517].  Conjunctival hyperemia (ocular surface redness) will be graded at each visit 
using the VBR grading sy stem as explained in section 3.[ADDRESS_1091222] visit will 
include: visual acuity (Snellen’s chart ), manifest refraction and intraocular pressure measurement . 
Clinically significant changes from baseline examination will be recorded on the adverse event forms.  
Corneal filaments are mucous tags  that are adherent to the surface of cornea. Mucoid films are mucous 
collections accumulating on the surface of the eye. The number of such mucus tags/ filaments will be 
counted on each clinical examination (slit -lamp examination).  
3.6 Other Study procedures : Ocular Surface Washings  
 
At the first (Baseline) and last treatment  (8 week)  visits, ocular surface washins will be collected as 
follows: 50 μL of artificial tear (Preservative Free Refresh Optive Sensitive, Allergan, Irvine, CA) was instilled into the lower fornix of the eye. The patient will be instructed to perform ductions in all 
directions, and after approximately 1 minute the conjunctival washings were collected with a 5 μL glass 
microcapi[INVESTIGATOR_149412] (Mirocaps Drummond Scientific, Broomall, PA) and transferred to a sterile 0.2 mL 
microcentrifuge tube. The samples will stored at cold temperature (approximately 4 degrees C) until 
further analysis. Ocular Surface washings will be transported to the laboratory and used for potential biomarker  analysis etc.   
[ADDRESS_1091223] Selection and Withdrawal  
4.1 Inclusion Criteria  
 
Patients will be eligible for the study if all of the following criteria are met:  
1. Sign and date the informed consent form approved by [CONTACT_1201]  
2. ≥ [ADDRESS_1091224] any 2 of the  following signs  in the same eye or a sign and symptom . 
a) Conjunctival staining present ≥ 1 (out of possible score of 6 per eye)  
b) Corneal  staining present ≥ 2 (out of a possible score of 15 per eye)  
c) Tear film  break up time (TFBUT) ≤ 7 seconds  
d) Schirmer’s test ≥ 0 to ≤ 9 mm/5min  
e) SLK pattern staining ≥ 1  
f) Meiboscale grade ≥ 2  
g) Validated Bulbar Redness ≥ 40  
h) Demonstrate symptoms of dry eye disease OSDI score of at least ≥ 13.  
i) Demonstrate Symptom Intensity Assessment of ≥ 3.  
4. Patient reported dry eye- related ocular symptoms for at least 6 months before the Screening 
Visit and use or desire to use artificial tears on average 2 times per day in the 2 weeks preceding the screening visit  
5. Intraocular pressure (IOP) ≥ 5 mmHg  and ≤ [ADDRESS_1091225] at the Screening 
Visit 
7. Be willing/able to return for all study visits  and to follow instructions from the study  
investigator and his/her staff  
8. Ocular Surface Wash Anti-Citrullinated Protein A ntibody (ACPA) value of > 4.[ADDRESS_1091226].   
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 38 of 59 
 
38 
 4.2 Exclusion Criteria  
 
Subjects will not be eligible for the study if any of the following criteria are met:  
 
1. Allergic to IVIG or any similar products, or excipi[INVESTIGATOR_791383] 4 mg/ml.  
2. Use of contact [CONTACT_791429] t 2-weeks  prior to the baseline Visit.  
3. Use of Allogenic serum or plasma eye drops  within  the last 2-weeks  prior to the baseline Visit . 
4. Unwilling to commit to no use of contact [CONTACT_269006] . 
5. Pregnant or nursing/lactating 
6. Participation in a study of an investigational drug or device within the 30 days  preceding the 
Scree ning Visit 
7. Current diagnosis of any of the following ocular conditions: 
i) Acute  allergic conjunctivitis  
ii)  Active  infection (e.g. bacterial, viral, protozoan or fungal infection of the cornea,  
conjunctiva, lacrimal gland, lacrimal sac or eyelids)  
iii) Active  intraocular inflammation (e.g., retinitis, choroiditis, uveitis)  
8. Ocular surgery (including cataract surgery), by [CONTACT_52168], within [ADDRESS_1091227] active drug/alc ohol dependence or abuse. 
13. Corneal epi[INVESTIGATOR_791384] 1 mm2 in either eye. 
14. Active ocular infection or ocular allergies . 
 Participants will be permitted to continue their chronic ocular treatments, including the use of artificial 
tears,  ointments, prescription eye drops (Restasis, Xiidra, Steroids) , eyelid massage, or warm 
compresses.  Subjects will be asked to maintain their ocular treatments unchanged in frequency of use 
for the duration of the study. Subjects wearing contact [CONTACT_13276]  (Soft b andage contact [CONTACT_791430]) or using serum tears will be asked to discontinue contact [CONTACT_791431] 2-
weeks  prior to being enrolled (Baseline visit) and will be required to not wear contact [CONTACT_791432] e duration of the study (until week 10 visit).  All systemic medications will continue 
unchanged.  
4.[ADDRESS_1091228] Recruitment and Screening  
 
Potential subjects will be recruited from the clinical practice of the investigator at the time of their 
routine eye examination visit. The clinical practice is located in the Illinois Eye and Ear Infirmary, 
Department of Ophthalmology and Visual Sciences, University of Illinois at Chica go (UIC) . Subjects  will 
include patients who have been diagnosed with DED  in the investigato r’s eye clinic (cornea clinic or the 
comprehensive eye clinic), in the Illinois Eye and Ear Infirmary . Furthermore, these patients would 
include only those who have had an ACPA value of > 4.[ADDRESS_1091229].  Patients diagnosed with DED, and willing to enter the study, may be referred to 
the PI’s clinic by [CONTACT_791433], as well as the ophthalmology departments at Loyola 
University Chicago, University of Chicago,  RUSH University, Cook Co unty Hospi[INVESTIGATOR_307],  and Northwestern 
University . These centers will be provided with ‘information sheets ’ to provide to subjects before they 
come to the PI’s clinic.  Although patients may be referred from these sites, no study procedures, 
including enrollment will be performed at any site, other than the PI’s clinic in Illinois Eye and Ear 
Infirmary . All subjects will be will be screened, recruited, and will attend all study related visits only at 
the PI’s clinic in Illinois Eye and Ear Infirmary . 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 39 of 59 
 
39 
  
Patients with Dry Eye Disease  (with Schirm er’s test ≥ 0 to ≤ 9 mm/5min  and annoying or activity limiting 
visual symptoms) will be approached by a member of the research staff to determine if the subject  
might be interested in participating in a research study. If the subject  is interested, the res earch staff 
member will describe the study. If the subject  is willing to enter the study,  the subject will be asked to 
review the study consent form, the PI [INVESTIGATOR_791385],  the study will be 
discussed to confirm the subject’s  understanding of the study, and to answer any questions that the 
subject might have. Once the subject demonstrates understanding of the study and  agrees to 
participate in the study,  the subject  will be asked to sign the informed consent form  in the presence of 
the PI. Consent will be obtained prior to performing any  screening tests  to determine eligibility.  
Screening procedures include documentation of DED as well as other assessments as detailed in 
section [ADDRESS_1091230] the right to withdraw subjects  from the study for the following 
reasons: when continuation may jeopardize the health of the subject , protocol violations, adverse 
events or concurrent conditions, administrative or other reasons.  
4.4.[ADDRESS_1091231]  remains in the study for safety evaluation, follow -up visits will be scheduled according to 
the schedule of visits and procedures found in the synopsis.  
5 Study Drug  
5.1 Description  
 The study drug, IVIG- eye drops , will be  compounded in the UIC Eye and Ear Infirmary (EEI) Pharmacy  
and supplied as a 4 mg/ml (0.4%) preservative free solution in single use vials  for administration as 
topi[INVESTIGATOR_211652].  The control group will receive Normal saline  eye drops as placebo.  
 Each subject  will receive either IVIG-eye drops  (study drug)  or Normal saline (placebo)  solution, as a 
single eye drop in each eye two times  a day  (BID) for eight  weeks.  Except for the first dose on Day1, 
subjects will self-administer  the test medication  eye drops at home.   
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- [ADDRESS_1091232] (neither the cost of the medication n or 
its dispensing  cost).  
5.2 Treatment Regimen  
 
Study drug group - IVIG-eye drops , 4mg/ml eye drops will be appl ied to both eyes b .i.d for 8 weeks.  
Control group – Normal saline  eye drops will be appli ed to both eyes b.i. d for [ADDRESS_1091233] two study groups. Subjects will be randomly 
assigned to one of two groups  (#1, #2) . One group will receive the study drug (IVIG 4mg/ml ; test 
group),  and the other group will receive placebo ( Normal saline; control group). We will use a computer -
based random code generator (Research Randomizer; http://randomizer.org/) to generate 1 set of 24 
non-unique, unsorted numbers with a range from 1 to 2 representing the group number  (#1/ #2). Each 
subjec t will be assigned a study identification (ID) number  at screening , e.g. Subject  #1, subjec t #2, and 
subject  #3 and so on. Based on the  randomizer generated table, subjec t #[ADDRESS_1091234] . For reproducibility purpose, we will document the 
final randomization schedule and the random SEED number used to generate the schedule. 
Randomization will be performed by [CONTACT_791434]'s pharmacy, and neither 
participants nor research staff will be aware of the assigned treatments.  The person conducting the 
randomization will remain masked as well.  
 The study  identification (ID) number will be used  on all study -related documents . The drug vial number 
will be linked to the subject  identification number.  
5.4 Preparation and Administration of Study Drug  
 
The study medications  will be stored , package d and dispensed from the UIC Eye and Ear Infirmary 
(EEI) Pharmacy . No modifications , except dilution with preservative free normal saline to achieve 
4mg/ml concentration,  will be made to the study medication constituents. The drug and placebo will be 
dispensed in sterile eye droppers  as single use vials, as explained below : 
 The study medications will be dispensed in sterile eye dropper s of 3.[ADDRESS_1091235]  (Flebogamma  or an equivalent IVIG preparation) is a single -use ampule containing 
5% (50mg/ml)  concentration of IVIG . Flebogamma (5%) will be diluted in normal saline to achieve IVIG -
eye drops 0.4% (4mg/ml). 0.5 m l to 1.0 ml of IVIG-eye drop (4mg/ml) will be transferred into one sterile 
eye droppers of 3.0  ml volume . IVIG-eye drops preparation (by [CONTACT_791435]) will be done at 
Illinois eye and ear infirmary (EEI) pharmacy , under standard aseptic precautions.  The eye droppers 
will be used by [CONTACT_791436] -dose applications.  
 One drop of the drug / placebo solution will be administered to  each eye. Therefore, 2 eyedroppers will 
be required per day. 
At each visits, subjects will receive 56 sterile multi- dose eye droppers that 
will be used as single- dose applications for 28 days.  Prepared eye droppers  will be placed in a dark 
(brown) colored zip-lock packet before being dispensed to the subject . The medication can be stored at 
room temp, away from direct strong light.  
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 41 of 59 
 
41 
 Instructions for Drug Use: 
 
1. Wash your hands thoroughly with soap and water.  
2. Check the dropper tip to make sure that it is not chipped or cracked. 
3. Avoid touching the dropper tip against your eye or anything else – eye drops and droppers 
must be k ept clean.  
4. While tilting your head back, pull down the lower lid of your eye with your index finger to  
form a pocket.  
5. Hold the dropper (tip down) with the other hand, as close to the eye as possible without 
touching it.  
6. While looking up, gently squeeze the  dropper so that a single drop falls into the pocket 
made by [CONTACT_791437]. Remove your index finger from the lower eyelid.  
7. Close your eye for [ADDRESS_1091236] dose of study medication on study Day 1 in the doctor’s  office and after 
completion of the study assessments will have the topi[INVESTIGATOR_791386] -administration.  
 Subjects will be provided with diaries to record the time of each dose and will also be a sked to record 
any adverse symptoms. In addition, they will be asked to make a note of any missed  doses together 
with the reason for the omission. Subjects will be asked to bring their diaries with them at the 4, and [ADDRESS_1091237] ’s me dical record,  
including all lubricants administered for Dry Eye Disease. These medications will be recorded in the 
case report form (CRF).  
 • For each medication taken, the following information will be collected:  
 
• Medication trade name  
• Eye that was treated, if applicable  
• Indication for which the medication was given 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 42 of 59 
 
42 
 • Date started  
• Date stopped   
• Dose of medication used . 
 
 In general, patients will be required to maintain the treatments that they were using at entry into the 
study throughout the follow -up period. Patients will be instructed to continue using the same brand of 
eye drops during the study as they were using at the screening visit. If patients are wearing contact [CONTACT_13276] (Soft bandage contact [CONTACT_791438])  or using serum tears, they will be asked to 
discontinue contact [CONTACT_791431] 2-weeks  prior to being enrolled (Baseline visit) 
and will be required to not wear contact [CONTACT_791439] (until 
week 10 visit) . This is necessary as one of the proposed exploratory study outcome measure is corneal 
Staining. Contact [CONTACT_791440][INVESTIGATOR_791387] a bandage that prevents corneal exposure to tear fluid inflammatory material s. Thus, 
because of over lappi[INVESTIGATOR_791388], it may not be possible to attribute 
any observed clinical benefit to IVIG-eye drops  treatment if contact [CONTACT_791441]. This 
approach has been used in other clinical  trials that have investigated the use of an anti -inflammatory 
agent in dry eye disease (NIH funded ‘Dry Eye Evaluation and Management (DREAM) study’).
[ADDRESS_1091238] lens wear may increase the risk of worsening of Dry Eye Disease (DED) during the 
wash -out period and during the course of the study. However, because other eye drop treatments will 
continue during the wash out period as well as during the course of the study, we do not expect any significant clinical worsening during the study. We do however expect the frequency of use of artificial 
tears to go up during the wash out period and during the course of the study.  
 Patients will be enrolled if they have been using their eye treatments for at least [ADDRESS_1091239]’s condition will be monitored by [CONTACT_099] (Principal Investigator) at each study visit, as well 
as at any interim visit (in case of adverse symptoms, as mentioned above). Any worsening of DED  or 
any adverse event due to the study drug will be recorded. In case of clinical worsening, based on the individual subject’s clinical condition, one or more of the following therapeutic decisions may be 
implemented: (1) Increasing /adding  the use of artificial tears or ointments  (2) Increasing /adding the  use 
of anti -inflammatory therapy ( Restasis / Xiidra/ Steroids)  or Serum Tears , (3) Withdrawal of the  use of 
study drug (if worsening occurs during the course of the study). The decision will be made by [CONTACT_099] (Principal Investigator) based upon his clinical judgment as per the individual subject’s clinical 
condition. If contact [CONTACT_791442]/or the study drug is 
withdrawn, the subject will be withdrawn  from the study. After any clinical worsening is noted, the 
subjects will be followed more closely (weekly) until complete resolution of symptoms and return to the 
subject’s previous baseline.  Subject s will be withdrawn from the study for presumed ocular allergic 
reaction to the product and ocular infection. The study will be stopped if the incidences of presumed 
ocular allergic reaction to the product and ocular infection surpasses 20% for each.  
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- [ADDRESS_1091240] receives study drug or placebo.  Subjects will be monitored by [CONTACT_079] [INVESTIGATOR_368205]. Any worsening of  DED or any adverse event (AEs) will be recorded and 
in the case of AEs followed to resolution. In case of clinical worsening/ adverse event(s), based on the  
individual subject’s clinical condition, one or more of the following therapeutic decisions may be implemented :  
(1) Increasing /adding  the use of  artificial tears  or ointments ,  
(2) Increasing/adding  the use of anti -inflammatory therapy ( Restasis / Xiidra/ S teroids) or Serum 
Tears   
(3) Discontinue the study drug.  
(4) Other eye drops/measures (example, cont act lens or surgeries), if indicated.   
The decision will be made by [CONTACT_079] [INVESTIGATOR_791389]’s clinical condition. If contact [CONTACT_791443]/or the study drug is discontinued, the 
subject will be withdrawn from the study. If an adverse event is severe enough to discontinue the subject from the study, the PI [INVESTIGATOR_791390]’s randomization code if it seems relevant 
to the treatment of his/her ocular condition at that time. He/ She will receive the treatment required for 
his/ her eye condition as per established clinical guidelines.  
5.8 Packaging  
 
The study medications will be dispensed in sterile eye dropper s of 3 ml volume, which will be used as 
single -dose applications . One drop of the placebo/ drug solution will be administered to each eye. 
Therefore 2 eye droppers will be required per day  because the placebo/drug is administered two times 
a day . At each visit, subjects will receive 56 sterile eye droppers that will be used as single- dose 
applications.  The eye droppers will be placed in a dark (brown) colored packet before being dispensed 
to the subject . A label with abbreviated information will be placed on each eye dropper.  The zip-lock 
packet  will include the subject’ s name, stage of visit, instructions for drug use and storage and the drug 
expi[INVESTIGATOR_320].   The label will also include the study name (abbreviated) and a statement  that the drug 
is investigational  for use only in this research study .” The first dose will  be administered to the subject  
by [CONTACT_791444] (visit 2 , day 1).  No separate packing will be done for the study medication to be used in 
the MD’s office.  The subjects will receive the 4 week s of remaining doses  in a dark packet to take 
home. 56 sterile  eye droppers  will be dispensed at each visit . 
5.9 Receiving, Storage, Dispensing and Return 
5.9.1  Receipt of Drug Supplies 
 
The UIC Investigational Drug Service (IDS)  or EEI Pharmacy  will order the study drug. The study drug 
will be stored in the Taylor Street/  EEI pharmacy  and dispensed to subjects as needed .  
5.9.[ADDRESS_1091241] from the EEI pharmacy on each treatment 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- [ADDRESS_1091242] dose that is administered in the clinic under the supervision of research 
personnel . The  study medication will not  be stored in the MD’s office , except when a subject receives 
his/her first dose, when the medication may be kept in the MD’s office  at room temp, away from direct 
strong light .  
5.9.[ADDRESS_1091243] treatment visit (day 1), the first study medication dose  will be administered to the subject  in 
the clinic and eye droppers  sufficient to last for [ADDRESS_1091244] treatment visit (day 1) and week 4.  No new drug eye droppers will 
be given on the week 8  visit.  
5.9.4  Return or Destruction of Study Drug 
 
At the completion of the study, there will be a final reconciliation of drug ordered/  received, drug 
consumed, and drug remaining.  Any discrepancies will be investigated, resolved, and documented.   
The used drug eye droppers will finally be disposed by [CONTACT_791445].  
[ADDRESS_1091245] (IRB).  
 Potential subjects will be recruited from the clinical practice of the principal investigator (PI) at the time of their  routine eye examination visit. The clinical practice is located at the Department of 
Ophthalmology and Visual Sciences, Eye and Ear Infirmary, [ADDRESS_1091246] been diagnosed with dry eye in the investigator’s eye clinic 
(cornea clinic or the comprehensive eye clinic), in the Illinois Eye and Ear Infirm ary. Patients may also 
be referred to the PI’s clinic by [CONTACT_791446], as well as the Ophthalmology 
departments at Loyola University Chicago, University of Chicago, RUSH University, Cook County 
Hospi[INVESTIGATOR_307], and Northwestern University. These centers will be provided with ‘information sheets’ to 
provide to subjects before they come to the PI’s clinic . The referring physicians shall inform the patients 
briefly about the study and provide t hem with the information sheet  (enclosed), but no  study related 
procedures (including screening and recruitment) will be performed at any location outside the PI’s clinic at UIC (Illinois Eye and Ear Infirmary). Even the patients referred to the PI’s clinic for possible 
enrollment in the study, will be screened and, if eligible, recruited in the study only at the PI’s clinic. The 
information sheet that will be given to the subjects are attached.  
Patients with established Dry Eye Disease (for at least 6 months, with S c h i r m e r ’ s  t e s t  ≥  0  t o  ≤  9  
mm/5min  and annoying or activity limiting visual symptoms) will be approached by a member of the 
research staff to determine if the patient might be interested in participating in a research study.  If the 
subject  is interested, the research staff member will describe the study. If the subject  is willing to enter 
the study,  the subject will be asked to review the study consent form, the PI [INVESTIGATOR_791391],  the study will be discussed to conform the sub ject’s understanding of the study,  and to 
answer any questions that the subject might have. Once the subject demonstrates understanding of the 
study and agrees to participate in the study,  the subject  will be asked to sign the informed consent form 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- [ADDRESS_1091247] the researchers in response to a flyer and information 
sheet provided by [CONTACT_791447] a visit to discuss the study and participate in the 
consent process. Consent will be obtained prior to screening to determine eligibility.  Subjects will be 
screened for eligibility, as per the inclusion/ exclusion criteria, and as detailed in section 6.5.1. Eligible 
subject s will be enrolled in the study.  
6.[ADDRESS_1091248]  Identification  
 
A study identification (ID) number will be assigned to each subject at  screening. This study ID number 
will be used on all study -related documents. To maintain confidentiality, the subject’s name [CONTACT_791459]. The master code list will link 
the subject MRN to the study ID number given to each subject. The master code list will be stored on 
password protected desktop in PI’s OFFICE in Lions of Illinois Eye Research Institute ( LIERI ). The data 
collected and master code list will be accessible only to the PI [INVESTIGATOR_791392]. The desktops will be password protected as well. Data will not be shared over the internet and 
will remain password protected. Confidentiality will be maintained. Data will be de- identified post 
publication of the study results  and for subjects determined to not meet eligibility criteria or who later 
decline participation in the consent process. 
6.[ADDRESS_1091249] s meeting the enr ollment criteria (see Sections 4.1) will be eligible for the study.   
6.[ADDRESS_1091250]’s medical/research charts, source documents, and CRFs as required. All ophthalmic procedures will be performed on both eyes.  
6.5.[ADDRESS_1091251] dose of study medication: 
• Demographic information including : birth date, gender, race or ethnic origin.  
• Medical History  including prior medication use and prior  procedures: Medical history will be 
obtained by [CONTACT_791448] a review of the following systems: 
cardiovascular, dermatologic, gastrointestinal, genitourinary, musculoskeletal, neurologic and 
respi[INVESTIGATOR_696]. An allergic history (including medications and food), substance abuse history 
(including alcohol) and a history of medication use (including prescription, OTC, and herbal 
products) during the past 30 days will also be completed. 
• Ophthalmic and Dry Eye Disease history  including: date when the Dry Eye Disease began, 
verification that the subject has had Dry Eye Disease for at least [ADDRESS_1091252] to treat Dry Eye Disease, previous procedures to treat Dry Eye Disease.  
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 46 of 59 
 
46 
 • Ophthalmic Examination  (slit lamp exa mination, Ocular Surface Redness Score,  Ocular Surface 
Disease Index, Lissamine  Dye staining, and a Schirmer  I test) 
• Pregnancy test , if applicable. Women of reproductive age will be asked to use a method of birth 
control that is acceptable to the subject and the study doctor. This may include oral 
contraceptive pi[INVESTIGATOR_3353], birth control implants/shots or patches, barrier methods or abstinence. 
Women of reproductive age will not be included in the study if they refuse to use any birth 
control measure, including abstinence. 
 
Subject s currently treating DED  with corticosteroids and/or Restasis will continue these treatments 
during the whole study.    If patients are wearing contact [CONTACT_13276] (Soft bandage contact [CONTACT_791449])  or using serum tears, they will be asked to discontinue contact [CONTACT_791431] 
2-weeks  prior to being enrolled (Baseline visit) and will be required to not wear contact [CONTACT_791450] (until week 10 visit). The study doctor will provide advice about 
decreasing DED  symptoms  with artificial tears, eyelid massage, or warm compresses.  
 
If the subject  agrees to enter the study  after screening , the  “Visit 2 Day 1 (Randomization and First 
treatment visit) ” will be scheduled. Visit [ADDRESS_1091253] lenses or use of serum tears and a 
washout period of 2-weeks  (±2 days ) will be needed before baseline visit (Visit 2) .   
 
In some subjects, detailed screening may not have to be performed as the subjects may have been followed and treated for Dry Eye in the PI’s clinic. In these cases, some or all of the screening test may 
have been performed during the subject’s routine dry eye care. These subjects will not be screened 
formally. An informed consent will be administered and subjects will be given an appointment for 
baseline visit examination. 
6.5.2   Visit 2  Day 1  (Randomization and First treatment visit)  
Prior to first dose (Baseline)  
 
• Record concomitant medications 
• Vital Signs : Blood pressure, Pulse, and Temperature taken while subject is  in a sitting 
position. 
• Visual Acuity  (Snellen’s chart ) with eye glasses (if applicable)  
• OSDI  
• Symptom Intensity  Assesment 
• Keratograph Oculus Redness Score  
> Non -invasive Keratography Tear Film Break -up Time (NIKBUT)  
• Schirmer I  test 
• Baseline Ophthalmic Examination (slit lamp examinati on, VBR) 
• Ocular surface wash collection for analysis (Potential biomarkers ) 
• InflammaDry Test for MMP -9 Protein  
• Lissamine Dye Corneal and Conjunctival staining 
• Adverse events since screening visit . 
 
- Randomization  (by [CONTACT_966])  
- Dispensing of study drug/placebo (by [CONTACT_37059])  
- Investigator/designee administers first dose  of study drug/ placebo  
 
Post -Dose  
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 47 of 59 
 
47 
 • Test Substance Tolerance (Visual Analogue Scale; VAS) 
• Subjects will be trained on how to self -administer the study eye drops and be given a 
sufficient supply to last for 4 week s to take home.  
• Subjects will receive a study diary on which to record the day/time of each dose and any 
adverse effects.  
• Post dose evaluation for any adverse effects . 
• Intraocular pressure measurement after topi[INVESTIGATOR_791393]  
6.5.3  Visit 3 : Week 4 (± 4 days)  
Treatment  Visit (after any dose for that day)  
 
• Review the subject’s diary and record changes in concomitant medication, deviations 
from drug schedule and adverse events. 
• Vital Signs : Blood pressure, Pulse, and Temperature taken while subject is  in a sitting 
positio n. 
• Visual Acuity  (Snellen’s chart ) with eye glasses (if applicable)  
• OSDI  
• Symptom Intensity Assessment , SGA and CGA  
• Test Substance Tolerance (VAS)  
• Baseline Ophthalmic Examination (slit lamp examinati on, VBR) 
 
- Dispensing of study drug/placebo (by [CONTACT_791451] ) 
- Returning of unused study drug/ placebo (by [CONTACT_791452])  
6.5.4  Visit 4 : Week 8 (± 4 days)  
Treatment Visit (after any dose for that day)  
 
• Review the subject’s diary and record changes in concomitant medication, deviations 
from drug schedule and adverse events.  
• Vital Signs : Blood pressure, Pulse, and Temperature taken while subject is  in a sitting 
position. 
• Visual Acuity  (Snellen’s chart ) with eye glasses (if applicable)  
• OSDI  
• Symptom Intensity Assessment, SGA and CGA  
• Test Substance Tolerance (VAS)  
• Keratograph Oculus Redness Score  
> Non -invasive Keratography Tear Film Break -up Time (NIKBUT)  
• Schirmer I  test 
• Baseline Ophthalmic Examination (slit lamp examinati on, VBR) 
• Ocular surface wash collection for analysis (Potential biomarkers ) 
• InflammaDry Test for MMP -9 Protein  
• Lissamine Dye Corneal and Conjunctival staining 
• Intraocular pressure measurement after topi[INVESTIGATOR_791393]  
- Returning of unused study drug/ placebo (by [CONTACT_791452])  
6.5.5  Visit 5 : Week 10 (± 4 days)  
Follow -Up Visit  
 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 48 of 59 
 
48 
 • Review the subject’s diary and record changes in concomitant medication and adverse 
events.  
• Vital Signs : Blood pressure , Pulse, and Temperature taken while subject is  in a sitting 
position. 
• Visual Acuity  (Snellen’s chart ) with eye glasses (if applicable)  
• OSDI  
• Symptom Intensity Assessment, SGA and CGA  
• Baseline Ophthalmic Examination (slit lamp examinati on, VBR) 
 
- Returning of patient diary (by [CONTACT_791453]) 
7 Statistical Plan  
7.1 Sample Size Determination  
 
As this is  a feasibility trial intended to guide the planning of lar ger future investigations , there are  no 
formal sample size calculations.65 The aim of the study is to recruit a sufficient number of patients to 
evaluate the acceptability and safety of the intervention and the study design. An outcome of this study 
will b e to estimate parameters such as the SD for a sample size calculation of a subsequent full -scale 
trial. A samp le of 24 patients (12 in each arm) is considered adequate for obtaining reliable sample size 
estimates.66, 67 To allow for a conservative attrition rate of 10%, we aim to recruit 28 patients into the 
trial.  
7.2 Statistical Methods  
 
Based on the classification of reasons for conducting pi[INVESTIGATOR_791394], in this pi[INVESTIGATOR_791395]:  (i) Process – recruitment rate , retenti on rate, (non)compliance or 
adherence rate; and (ii) Scientific – safety (adverse event/SAE rate), tolerability, and efficacy, including 
reduction in clinical signs and symptoms (OSDI, Corneal staining, Redness etc  as detailed in section 
3.4) and treatment effect size. We will calculate the observed rate with 95% confidence interval for each 
rate by [CONTACT_1570]. Other descriptive statistics, including median with interquartile or mean with standard deviation for continuous variables and frequency with percentage for categorical variables will 
be reported as well. To estimate the preliminary efficacy under the scientific category, one eye (target 
eye) will be selected at screening visit as follows: (i) if only 1 eye meets inclusion criteria, this eye is used; (ii) if both eyes meet inclusion criteria, the eye with the higher corneal stain score is used; (iii) if 
both eyes have the same corneal stain  score, then the one with the lower Schirmer I score is used; (iv) 
if both eyes have same scores, the right eye is used. Secondary analyses will be performed for the 
non-target eye as well. Due to the nature of this feasibility study, any efficacy statistical tests and 
adjusted analyses will not be conducted.  Detailed data validation will examine completeness, ex istence 
and accuracy of collected data to assess data quality and identify missing and conflicting data.  
Statistical analysis will be performed on an intention- to-treat basis i.e., inclusion of all patients randomly 
assigned, regardless of adherence, actual treatment received, and subsequent withdrawal of treatment and/or deviation from the protocol and per -protocol (i.e., inclusion of those who completed the 
treatment as planned)[ADDRESS_1091254] Population(s) for Analysis  
 
Statistical analysis will be performed on : (i) intention- to-treat basis (i.e., inclusion of subjects  randomly 
assigned, regardless of adherence, actual treatment received, and subsequent withdrawal of treatment 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 49 of 59 
 
49 
 and/or deviation from the protocol ); and (ii) per-protocol basis (i.e., inclusion of subjects  who completed 
the treatment as planned ).  
8 Safety and Adverse Events  
8.1 Adverse Event Definitions 
 
The following are specific definitions of terms guided by [CONTACT_394646] 
(ICH) Guidelines for Good Clinical Practice (GCP) and the U.S. Code of Federal Regulations that apply 
to this section:  
 
Adverse Event:  Any untoward medical occurrence in a subject  or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have to have a causal 
relationship with this treatment.  An AE is any unfavorable and unintended sign, symptom, or disease 
temporally associated with the use of an investigational medicinal product (IMP) or other protocol -
imposed intervention, regardless of attribution. This includes the following:  
• AEs not previously observed in the subject that emerge during the protocol -specified AE 
reporting period, including signs or symptoms associated with Dry Eye Disease (DED) that we re 
not present prior to the AE reporting period.  
• Complications that occur as a result of protocol -mandated interventions.  
• If applicable, AEs that occur prior to assignment of study treatment associated with medication washout, no treatment run- in, or other  protocol -mandated intervention.  
• Preexisting medical conditions (other than the condition being studied) judged by [CONTACT_95048] -specified AE reporting period 
 Subject s will be reminded to inform the study staff of any adverse effects that they have experienced or 
are experiencing after the first administration of study drug. In addition, subjects will record adverse events in their diary throughout the study. All reports of adverse events during the study will be recorded on an Adverse Event Case Report Form (CRF).  The subject should not be prompted about 
any adverse events that may occur during this trial.  
 
All AEs and SAEs whether volunteered by [CONTACT_423], discovered by [CONTACT_168204], or detected through physical examination, laboratory test, or other means will be reported 
appropriately. For each adverse event, the following information will be recorded on the subject’s Case 
Report Form(s): onse t date, end date or continues, intensity, duration, relationship to test patch, action 
taken, and outcome.  If a subject experiences a serious adverse event (SAE), study staff may 
discontinue the subject from study participation. The study staff must notify  the IRB within [ADDRESS_1091255] to notify the research facility should any adverse event occur within 7 days of study completion. (For definitions of an AE and SAE, see 
below). Subjects who withdraw due to an adverse event may be replaced.  
 
• Serious Adverse Event:  An AE should be classified as an SAE if the following criteria are met:  
1. It results in death (i.e., the AE actually causes or leads to death.).  
2. It is life -threatening  (i.e., the AE , in the view of the investigator, places the subject at 
immediate risk of death. It does not include an AE that, had it occurred in a more 
severe form, might have caused death.). 
3. It requires or prolongs inpatient hospi[INVESTIGATOR_059]. 
4. It results in persistent or significant disability/incapacity  (i.e., the AE results in 
substantial disruption of the subject’s ability to conduct normal life functions).  
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 50 of 59 
 
50 
 5. It results in  a congenital anomaly/  birth defect  in a neonate/infant born to a mother 
exposed to the investigational medicinal product (IMP).  
6. It is considered a significant medical event by [CONTACT_509026] (e.g., my jeopardize the subject or may requires medical or surgical 
intervention to prevent any of the occurrences listed  above.  
 To ensure consistency of AE and SAE causality assessments, the following general guideline will be 
applied:  
 Yes 
There is a plausible temporal relationship between the onset of the AE and administration of the IVIG , 
and the AE cannot be readily explained by [CONTACT_423]’s clinical state, intercurrent illness, or 
concomitant therapi[INVESTIGATOR_014]; and/or the AE follows a known pattern of response to the IVIG; and/or the AE 
abates or resolves upon discontinuation of the IVIG or dose reduction and, if applicable, reappears 
upon re -challenge
 
 No 
Evidence exists that the AE has an e tiology other than the IVIG  (e.g., preexisting medical condition, 
underlying disease, intercurrent illness, or concomitant medication); and/or the AE has no plausibl e 
temporal relationship to IVIG  administration (e.g., cancer diagnosed [ADDRESS_1091256] dose of study 
drug)  
 
Life- threatening:  Any adverse drug experience in which the subject was at risk of death at the time of 
the event. It does not refer to an event which hypothetically might have caused death if it were more 
severe.  
Expected adverse event:  Expected adverse events are those adverse events that are listed or 
characterized in the Package Insert (P.I) or current Investigator Brochure (I.B).  
 
Unexpected adverse event:  Any adverse event, the specificity or severity of which is not consistent 
with the current Investigator’s Brochure.  
8.2 Classification of Adverse Events by [CONTACT_791454]/adverse events will be graded according to the following definitions to code  the intensity of 
the ev ent. 
 Mild:  Usually transient, requiring no special treatment, and does not interfere with the subject’s daily 
activities.  
Moderate:  Traditionally introduces a low level of inconvenience or concern to the subject and may 
interfere with daily activities, but are usually relieved by [CONTACT_14212].  
Severe:  Causes an interruption of the subject’s usual daily activity and traditionally required systemic 
drug therapy or other treatment.  
Note: If the intensity of an adverse event changes, the event will be reentered as a separate event.  
There is a distinction between the severity and the seriousness of an adverse event. Severity is a 
measurement of intensity; thus, a severe reaction is not necessarily a serious adverse event. For 
example, a headache may be severe in intensity, but would not be serious unless it met one of the criteria for serious adverse events listed previously.  
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 51 of 59 
 
51 
 8.3 Action(s) Taken  
One or more of the following will be recorded by [CONTACT_791455]:  
 
• No action taken  
• Discontinued study drug (Subject withdrawn due to this adverse event)  
• Administered therapy  
• Hospi[INVESTIGATOR_67477] (due to this adverse event)  
• Other (specify) - includes tests, labs confirming reaction  
8.4 Outcome  
 
The status of each adverse event will be recorded as follows, if applicable: SAE:  Indicates that the 
adverse event met the criteria of a serious adverse event (SAE) and the SAE was reported to the IRB. 
Caused Withdrawal : Indicates that the adverse event caused the subject’s withdrawal  from the study.   
8.[ADDRESS_1091257] ’s condition is stable, whichever 
is earlier. The Investigator will take all appropriate and necessary therapeutic measures required for 
resolution of the adverse event. Any medication necessary for the treatment of an adverse event must 
be recorded on the concomitant medication case report form. If more than one distinct adverse event 
occurs, each event should be recorded separately. Procedures such as surgery should not be recorded 
as adverse events. However, the medical condition for which the procedure was performed should be 
reported if it meets the definition of adverse event as described previously.  
8.6 Serious Adverse Event Reporting 
 
All Serious Adverse Events (SAE) that occur during the course of the study, including death, which are 
unanticipated require reporting to the IRB within [ADDRESS_1091258] dose of study drug and continuing until the 
end of the study. The minimum information to be provided includes:  
 
1. Protocol Number  
2. Initial reporter  
3. Subject  identification  
4. Nature and date of the event/effect  
5. Country of  the event/effect  
6. Severity of the event/effect  
7. Reporting criteria  
8. Narrative description of the event/effect  
9. Outcome if known 
10. Causal relationship to the investigational product  
11. Additional and follow -up information as requested by [CONTACT_7195] . 
 Event s requiring reporting to the IRB within 15 business days of the investigator becoming aware  
include:  
  
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 52 of 59 
 
52 
 1. Local adverse events or problems that are unanticipated and, while not meeting the criteria of 
serious, indicate research is associated with a greater risk of harm to participants or others than 
previously known.  
2. New information indicating an unexpected change to the risks or benefits of the research (i.e., an unanticipated problem).  
3. Administrative hold by [CONTACT_1697], regulatory authorities or other entities.  
8.[ADDRESS_1091259] describe the departure from the protocol 
and state the reason.  
8.8 Data Safety Management Plan  
 
The study protocol will be reviewed and approved by [CONTACT_142596].  Adverse events and compliance will 
be monitored. Research staff w ill be trained on the protocol requirements and data collection methods 
before completing study related procedures. Privacy, coding, storage: Research staff will be trained on the protocol requirements and data collection methods before completing study related procedures.  
Random study ID numbers will be assigned to study subjects. A master code list will link the subject 
MRN to the study ID number. The data collected will be stored on PI’s desktop in a HIPPA compliant 
encrypted folder at the Ear and Eye Infirmary and Lions Eye Research building. The data collected, 
master code list will be accessible only to the PI [INVESTIGATOR_791396]. The 
desktops will be password protected as well.  
  
All Serious Adverse Events (SAE) that occur during the course of the study, and possibly related to the 
study intervention, including death, which are unanticipated will be reported to the IRB within 5 
business days of the investigator becoming aware. A copy of the report will be sent to the FDA.  
 
Events requiring reporting to the IRB within 15 business days of the investigator becoming aware 
include:  
 
• Local adverse events or problems that are unanticipated and, while not meeting the criteria of 
serious, indicate research is associated with a greater risk of harm to participants or others than 
previously known.  
• New information indicating an unexpected change to the risks or benefits of the research (i.e., 
an unanticipated problem).  
 A copy of this report will be sent to the FDA.  
 
The minimum infor mation to be provided includes:  
 
1. Protocol Number  
2. Initial reporter  
3. Subject identification  
4. Nature and date of the event/effect  
5. Country of the event/effect  
6. Severity of the event/effect  
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 53 of 59 
 
53 
 7. Reporting criteria  
8. Narrative description of the event/effect  
9. Outcome if kn own 
10. Causal relationship to the investigational product  
11. Additional and follow -up information as requested by [CONTACT_7195]. 
8.[ADDRESS_1091260] with an active practice in the area of Dry Eye Disease, including those with Meibomian 
Gland Disease. He routinely takes care of patients with severe ocular surface disease.  He's also the 
director of Dry Eye service at UIC. Therefore, he's well qualified to recognize the symptoms and clinical 
signs of an adverse event. [CONTACT_137279] has been the PI [INVESTIGATOR_791397]. Therefore, he has experience in data and safety 
monitoring.   
 The Principal Investigator [INVESTIGATOR_791398]. Safety 
monitoring will include careful assessment and appropriate reporting of adverse events.  Subjects will 
be reminded to inform the study staff of any  adverse effects that they have experienced or are 
experiencing after the first administration of study drug.  Subjects will be provided with diaries to record  
at home the time of each dose and any adverse symptoms. All reports of adverse events during the 
study will be recorded on an Adverse Event Case Report Form (CRF). In addition, subjects will be 
asked to make a note of any missed doses together with the reason for the omission.  A member of the 
research staff will review diary entries with the subject  at each study visit.  Subjects will be asked to 
bring back the left -over drug at each study visit. The amount of drug remaining in the used vial will also 
give an estimate of the compliance.  
[ADDRESS_1091261] of 1996 (HIPAA).  Those regulations require a 
signed subject authorization informing the subject of the following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why  
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
 In the event that a subject revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], 
retains the ability to use all information collected prior to the revocation of subject authorization.  For subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain 
permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study 
period.  
10 Source Documents  
 
Source data is all information, original records of clinical findings, observations, or other activities in a 
clinical trial necessary for the reconstruction and evaluation of the trial.  Source data are contained in 
source documents.  Examples of these original documents, and data records include: hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_791399]-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- [ADDRESS_1091262] files, and records kept at the pharmacy, at the 
laboratories, and at medico- technical departments involved in the clinical trial.  
10.1 Records Retention  
 
It is the investigator’s responsibility to retain study essential documents for the full duration of the study. This includes, but is not limited to, the following: completed Informed Consent forms, Case Report 
Forms, AE/SAE report forms, all study correspondence and associated documentation. Per  regulations, 
these records should be maintained for a period of two years following a marketing approval for the study drug or two years following shipment and delivery of the drug for investigational use is 
discontinued.  
11 Ethical Considerations  
 
This study is to be conducted according to US and international standards of Good Clinical Practice 
(FDA Title 21 part 312 and International Conference on Harmonization guidelines), applicable 
government regulations and Institutional research policies and procedure s. 
 This protocol and any amendments will be submitted to a properly constituted independent Institutional 
Review Board (IRB), in agreement with local legal prescriptions, for formal approval of the study 
conduct.  The decision of the IRB concerning the conduct of the study will be made  in writing to the 
investigator.  The study may not commence until IRB approval is granted.  
 All subjects for this study will be provided a consent form describing this study and providing sufficient 
information for subjects  to make an informed decision about their participation in this study.  This 
consent form will be submitted with the protocol for review and approval by [CONTACT_14884].  The 
formal consent of a subject, using t he IRB-approved consent form, must be obtained before that subject 
undergoes any study procedure.  The consent form must be signed by [CONTACT_791456], and the investigator -designated research professional obtaining the consent.   
12 Study Finances  
12.1 Funding Source  
 
(i) UIC Office of Technology Management Proof of Concept Award 
(ii) Departmental funds   
12.[ADDRESS_1091263] with this study (patent ownership, royalties, or financial 
gain greater than the minimum allowable by [CONTACT_1385], etc.) must have the conflict reviewed by a 
properly constituted Conflict of Interest Committee with a Committee- sanctioned conflict management 
plan.  All UIC investigators will follow the University conflict of interest policy.  
12.[ADDRESS_1091264] Stipends  or Payments  
 The subjects  will receive $50 cash for baseline and week 8 visit and $[ADDRESS_1091265] 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- [ADDRESS_1091266] complete s the 
study, the total amount of compensation will be $180.00.  
  
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 56 of 59 
 
56 
 13 References:  
 
1. Fisher LD , Dixon DO , Herson J , et al . Intention to treat in clinical trials. Statistical issues in 
drug research and development. [LOCATION_001]: Marcel Dekker, 1990:331– 50. 
2. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting 
parallel group randomized trials. BMJ 2010;340:c332.doi:10.1136/bmj.c332.  
3. Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, de Paiva CS, Gomes JAP, Hammitt KM, Jones L, Nichols JJ, Nichols KK, Novack GD, Stapleton FJ, Willcox MDP, Wolffsohn JS, Sullivan DA. TFOS DEWS II Report Executive Summary Ocul Surf. [ADDRESS_1091267];15(4):802 -812. 
4. Suvarna P. Phadatare, Munira Momin, Premanand Nighojkar, Sonali Askarkar, and Kamalinder 
K. Singh, “A Comprehensive Review on Dry Eye Disease: Diagnosis, Medical Management, Recent Developments, and Future Challenges,” Advances in Pharmaceutics, vol. 2015, Article 
ID 704946, 12 pages, 2015. https://doi.org/10.1155/2015/704946
 
5. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, 
Ogawa Y, Perez V, Uchino Y, Yokoi N, Zoukhri D, Sullivan DA. TFOS DEWS II  pathophysiology 
report Ocul Surf. 2017 Jul; 15(3):438 -510 
6. Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71 -81; quiz 82.  
7. Pflugfelder SC, de Paiva CS, Li DQ, Stern ME. Epi[INVESTIGATOR_018] -immune cell interaction in dry eye. 
Cornea. 2008;[ADDRESS_1091268] 1(0 1):S9- 11. 
8. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune -mediated ocular surface 
disorder. Arch Ophthalmol. 2012;130(1):90- 100. 
9. Dor M, Eperon S, Lalive PH, Guex -Crosier Y, Hamedani M, Salvisberg C, Turck N. Investigation 
of the global protein content from healthy human tears. Exp Eye Res. [ADDRESS_1091269] 13;179:64- 74 
10. CHODIRKER WB, TOMASI TB Jr. GAMMA -GLOBULINS: QUANTITATIVE RELATIONSHIPS 
IN HUMAN SERUM AND NONVASCULAR FLUIDS. Science. 1963 Nov 22;142(3595 ):1080 -1. 
11. Agarwal S, Cunningham -Rundles C. Assessment and clinical interpretation of reduced IgG 
values. Ann Allergy Asthma Immunol. 2007 Sep;99(3):281- 3. 
12. Stuchell RN, Feldman JJ, Farris RL, Mandel ID. The effect of collection technique on tear composition. Invest Ophthalmol Vis Sci. 1984 Mar;25(3):[ADDRESS_1091270] Ophthalmol 
Vis Sci. 2000 May;41(6):1270- 9. 
14. Barisani -Asenbauer T, Inic -Kanada A, Belij S, Marinkovic E, Stojicevic I, Montanaro J, Stein E, 
Bintner N, Stojanovic M. The ocular conjunctiva as a mucosal immunization route: a profile of the immune response to the model antigen tetanus toxoid. PLoS One. 2013 Apr 26;8(4):e60682.  
15. Hall JM, Pribnow JF. IgG and IgA antibody in tears of rabbits immunized by [CONTACT_12523][INVESTIGATOR_791400]. Invest Ophthalmol Vis Sci. 1989 Jan;30(1):138 -44. 
16. Borderie VM1, Gineys R, Goldschmidt P, Batellier L, Laroche L, Chaumeil C. Association of 
anti-herpes simplex virus IgG in tears and serum with clinical presentation in patients with 
presumed herpetic simplex keratitis. Cornea. 2012 Nov;31(11):1251- 6. 
17. Skwor T, Kandel RP, Basravi S, Khan A, Sharma B, Dean D. Characterization of humoral 
immune responses to chlamydial HSP60, CPAF, and CT795 in inflammatory and severe trachoma. Invest Ophthalmol Vis Sci. [ADDRESS_1091271];51(10):5128- 36. 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 57 of 59 
 
57 
 18. Zandbelt M, te Boome L, Klasen I, van de Putte L, van den Hoogen F. Tear fluid measurement 
of anti -SS-A and anti -SS-B antibody in anti- SS-A and anti -SS-B seronegative Sjögren's 
syndrome patients. Clin Exp Rheumatol. 2009 May -Jun;27(3):536.  
19. Amparo F, Schaumberg DA, Dana R. Comparison of Two Questionnaires for Dry Eye Symptom Assessment: The Ocular Surface Disease Index and the Symptom Assessment in  Dry 
Eye. Ophthalmology. 2015;122(7):1498- 503. 
20. Saboo US, Amparo F, Abud TB, Schaumberg DA, Dana R. Vision- Related Quality of Life in 
Patients with Ocular Graft -versus -Host Disease. Ophthalmology. 2015;122(8):1669- 74. 
21. Lin H, Yiu SC. Dry eye disease: A review of diagnostic approaches and treatment s.  Saudi 
J Ophthalmol. 2014;28(3):173 -81. 
22. Martín -Nares E, Hernández -Molina G. Novel autoantibodies in Sjögren's syndrome: A 
comprehensive review. Autoimmun Rev. 2018 Dec 18. pii: S1568 -9972(18)[ZIP_CODE]- 1. 
23. Dourmishev LA, Guleva DV, Miteva LG. Intravenous Immunoglobulins: Mode of Action and Indications in Autoimmune and Inflammatory Dermatoses. Int J Inflam. 2016;2016:3523057. PMID: 26885437  
24. Tellier Z. Human immunoglobulins in intraocular inflammation. Ann N Y Acad Sci. 2007 Sep;1110:337 -47. 
25. LeHoang P, Cassoux N, George F, Kullmann N, Kazatchkine MD. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm. 2000 
Mar;8(1):[ADDRESS_1091272] autoantibodies in pooled normal human 
polyspecific Ig. J Immunol. 1989 Dec 15;143(12):4104- 9. 
27. Rossi F, Dietrich G, Kazatchkine MD. Anti- idiotypes against autoantibodies in normal 
immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev. 1989 Aug;110:135- 49. 
28. Tava kolpour S1. The role of intravenous immunoglobulin in treatment of mucous membrane 
pemphigoid: A review of literature. J Res Med Sci. 2016 Jun 14;21:37.  
29. Gonzalez -Quintela A1, Alende R, Gude F, Campos J, Rey J, Meijide LM, Fernandez -Merino C, 
Vidal C. Serum  levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their 
relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol. 2008 Jan;151(1):[ADDRESS_1091273] Ophthalmol Vis 
Sci. 2006 Jun;47(6):2438- 44. 
31. Bradley JC, Bradley RH, McCartney DL, Mannis MJ. Serum growth factor analysis in dry eye 
syndrome.  Clin Exp Ophthalmol. 2008 Nov;36(8):717- 20. 
32. van Setten GB, Viinikka L, Tervo T, Pesonen K, Tarkkanen A, Perheentupa J. Epi[INVESTIGATOR_791401] a constant component of normal human tear fluid. Graefes Arch Clin Exp Ophthalmol. 1989;227(2):184 -7. 
33. Poon AC, Geerling G, Dart JK, Fraenkel GE, Daniels JT. Autologous serum eyedrops for dry eyes and epi[INVESTIGATOR_50024]: clinical and in vitro toxicity studies. Br J Ophthalmol. [ADDRESS_1091274];85(10):1188- 97. 
34. Tsubota K1, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epi[INVESTIGATOR_791402]. Ophthalmology. [ADDRESS_1091275];106(10):1984 -9. 
35. Liu L, Hartwig D, Harloff S, Herminghaus P, Wedel T, Geerling G. An optimised protocol for the 
production of autologous serum eyedrops. Graefes Arch Clin Exp Ophthalmol. 2005 Jul;243(7):706- 14. 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- [ADDRESS_1091276]. Eye (Lond). 2009 Feb;23(2):290- 3. 
37. Matsumoto Y, Dogru M, Goto E, Ohashi Y, Kojima T, Ishida R, Tsubota K. Autologous serum 
application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004 Jun;111(6):1115-20. 
38. Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R, Kuwana M, Tsubota K, Ikeda Y, Oguchi Y. Autologous serum eye drops for the treatment of severe dry eye in patients 
with chronic graft -versus -host disease. Bone Marrow Transplant. 2003 Apr;31(7):579- 83. 
39. Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I, Shimmura S. Treatment of dry eye by 
[CONTACT_791457]ögren's syndrome. Br J Ophthalmol. 1999 Apr;83(4):390- 5. 
40. Young AL, Cheng AC, Ng HK, Cheng LL, Leung GY, Lam DS. The use of autologous serum 
tears in persistent corneal epi[INVESTIGATOR_50024]. Eye (Lond). 2004 Jun;18(6):609- 14. 
41. Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. 
Br J Ophthalmol. 2004 Nov;88(11):1467 -74. 
42. Dogru M, Tsubota K. Pharmacotherapy of dry eye. Expert Opin Pharmacother. 2011 
Feb;12(3):325 -34. 
43. Noble BA, Loh RS, MacLennan S, Pesudovs K, Reynolds A, Bridges LR, Burr J, Stewart O, 
Quereshi S. Comparison of autologous serum eye drops with conventional therapy in a 
randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol. 2004 
May;88(5):647- 52. 
44. Celebi AR1, Ulusoy C, Mirza GE. The efficacy of autologous serum eye drops for severe dry 
eye syndrome: a randomized double- blind crossover study. Graefes Arch Clin Exp Ophthalmol. 
2014 Apr;252(4):619 -26. 
45. Jeng BH, Dupps WJ Jr. Autologous serum 50% eyedrops in the treatment of persistent corneal 
epi[INVESTIGATOR_50024]. Cornea. 2009 Dec;28(10):1104 -8. 
46. Alvarado Valero MC, Martínez Toldos JJ, Borras Blasco J, Almiñana Almiñana A, Pérez Ramos 
JM. Treatment of persistent epi[INVESTIGATOR_791403]. Arch Soc Esp 
Oftalmol. 2004 Nov;79(11):[ADDRESS_1091277] 70 eyes. Klin Monbl Augenheilkd. 2001 
Nov;218(11):[ADDRESS_1091278] MA, DeLoss K, Mian SI. Long -term use 
of autologous serum 50% eye drops for the treatment of dry eye disease. Cornea. 2014 Dec;33(12):1245 -51. 
49. Jirsova K, Brejchova K, Krabcova I, Filipec M, Al Fakih A, Palos M, Vesela V. The applic ation of 
autologous serum eye drops in severe dry eye patients; subjective and objective parameters before and after treatment. Curr Eye Res. 2014 Jan;39(1):[ADDRESS_1091279] of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective 
randomized case- control study. Am J Ophthalmol. 2005 Feb;139(2):242- 6. 
51. Urzua CA, Vasquez DH, Huidobro A, Hernandez H, Alfaro J. Randomized double- blind clinical 
trial of autologous serum versus artificial tears in dry eye syndrome. Curr Eye Res. 2012 
Aug;37(8):684- 8. 
52. Chiang CC, Chen WL, Lin JM, Tsai YY. Allogeneic serum eye drops for the treatment of persistent corneal epi[INVESTIGATOR_17754]. Eye (Lond). 2009 Feb;23(2):290- 3. 
IVIG-eye drops  treatment for Dry Eye Disease  
Version: 3 .0; 04-09- 2019 Page 59 of 59 
 
59 
 53. Harritshøj LH, Nielsen C, Ullum H, Hansen MB, Julian HO. Ready -made allogeneic ABO -
specific serum eye drops: production from regular male blood donors, clinical routine, safety and 
efficacy. Acta Ophthalmol. 2014 Dec;92(8) :783-6. 
54. Espi[INVESTIGATOR_53067] A, Hjorth -Hansen H, Aasly K, Teigum I, Sivertsen G, Seghatchian J. Implementation 
of a standardised method for the production of allogeneic serum eye drops from regular blood donors in a Norwegian University Hospi[INVESTIGATOR_307]: Some methodological aspects and clinical considerations. ransfus Apher Sci. 2015 Aug;53(1):88 -91. 
55. van der Meer PF1, Seghatchian J2, de Korte D2. Autologous and allogeneic serum eye drops. The Dutch perspective. Transfus Apher Sci. 2015 Aug;53(1):99 -100. doi: 
10.1016/j.transci. 2015.05.017. Epub 2015 Jun 9.  
56. van der Meer PF, Seghatchian J, Marks DC. Quality standards, safety and efficacy of blood-
derived serum eye drops: A review. Transfus Apher Sci. 2016 Feb;54(1):164- 7. 
57. Chiang CC, Lin JM, Chen WL, Tsai YY. Allogeneic serum eye drops for the treatment of severe 
dry eye in patients with chronic graft -versus -host disease. Cornea. 2007 Aug;26(7):[ADDRESS_1091280];28(5):479- 83. 
59. Stenwall PA, Bergström M, Seiron P, Sellberg F, Olsson T, Knutson F, Berglund D. Improving 
the anti -inflammatory effect of serum eye drops using allogeneic serum permissive for 
regulatory T cell induction. Acta Ophthalmol. 2015 Nov;93(7):654- 7. 
60. Marchand M, Harissi -Dagher M, Germain M, Thompson P, Robert MC. Serum drops for ocular 
surface disease: national survey of Canadian cornea specialists. Can J Ophthalmol. 2018 Jun;53(3):266 -271. 
61. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the 
Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615– 621. 
62. Miller KL, Walt JG, Mink DR, Satram -Hoang S, Wilson SE, Perry HD, Asbell PA, Pflugfelder SC. 
Minimal clinically important difference for  the ocular surface disease index. Arch Ophthalmol. 
2010;128:94 -101. 
63. Schulze MM, Jones DA, Simpson TL. The development of validated bulbar redness grading scales. Optom Vis Sci 2007;84:[ADDRESS_1091281] for Treatment of Dry Eye Disease: A 
Randomized Clinical Trial. JAMA Ophthalmol. 2013;18:1 -9. 
65. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pi[INVESTIGATOR_7602]: recommendations 
for good practice. J Eval Clin Pract 2004;10:307– 12. 
66. Sim J, Lewis M. The size of a pi[INVESTIGATOR_141106] a clinical trial should be calculated in relation to 
considerations of precision and efficiency. J Clin Epi[INVESTIGATOR_5541] 2012;65:301– 8. 
67. Julious SA. Sample size of 12 per group rule of thumb for a pi[INVESTIGATOR_799]. Pharm Stat2005;4:287–91. 